CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 1  
 
 
ACTIV- 6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed 
Medications 
 
[STUDY_ID_REMOVED] 
 
 
IND Number:  
 155481  
Principal Investigator:  [INVESTIGATOR_88471], MD, MHS  
Duke Clinical Research Institute  
[ADDRESS_1011234]. 
Durham, NC [ZIP_CODE] 
Phone: [PHONE_9077] 
Email: [EMAIL_1789]  
Co-Principal 
Investigator/IND 
Sponsor : Susanna Naggie, MD, MHS  
Duke Clinical Research Institute  
[ADDRESS_1011235]. 
Durham, NC [ZIP_CODE] 
Phone: [PHONE_9078] 
Email: [EMAIL_1790]  
Data Coordinating 
Center Investigator  Chris Lindsell , PhD 
Vanderbilt University School of Medicine 
[ADDRESS_1011236], Rm [ZIP_CODE] 
Nashville, T N [ZIP_CODE] 
Phone: [PHONE_13558] 
Email: [EMAIL_1777]  
Lead   
Funding Agency:  
 National Center for Advancing Translational Sciences  
Version:  
 6.0 
Date:  17JUN2022 
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 2 Statement of Compliance  
 
This trial will be conducted in compliance with the International Council for Harmonisation 
(ICH) E6 ( R2) guideline for Good Clinical Practice (GCP), and the applicable regulatory 
requirements from the [LOCATION_002] (US) Code of Federal Regulations (CFR), including 45 CFR 
46 (Human Subjects Protection); 21 CFR 312 (Investigational New Drug); 21 CFR 50  (Informed 
Consent), and 21 CFR 56 (Institutional Review Board).  
All individuals who are responsible for the conduct, management, or oversight of this study have 
completed Human Subjects Protection and ICH GCP Training. 
 
 
  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011237] read the protocol, including all appendices, and the package insert (s)/product label (s), and 
I agree that the protocol contains all necessary details for my staff and me to conduct this study 
as described. I will personally oversee the conduct of this study as outlined herein and will make 
a reasonable effort to complete the study within the time designated. I agree to make all 
reasonable efforts to adhere to the attached protocol.  
I will provide all study personnel under my supervision with copi[INVESTIGATOR_436306]’s representative. I will discuss this 
material with study personnel to ensure that they are fully informed about the efficacy and safety 
parameters and the conduct of the  study in general. I am aware that, before beginning this study, 
the IRB, or equivalent oversite entity must approve this protocol in the clinical facility where it 
will be conducted.  
I agree to obtain informed consent from participants, as required by [CONTACT_740099] I CH guidelines. I further agree to report to the sponsor 
or its representative any adverse events in accordance with the t erms of this protocol and the U S 
CFR, Title 21, part 312.64, ICH GCP 4.11. I further agree to ensure the study is conducted in accordance with the provisions as stated and will comply with the prevailing local laws and customs.  
  
   
Site Principal Investigator [CONTACT_5627] (Print)   
   
   
Site Principal Investigator [INVESTIGATOR_88473] -6 Protocol [v6.0] 
 
 4 Table of Contents  
1. Protocol Summary  ........................................................................................................12  
1.1. Synopsis  ..........................................................................................................................12  
1.2. Schema  ............................................................................................................................19  
2. Introduction ...................................................................................................................21  
2.1. Study Rationale  ...............................................................................................................21  
2.2. Background .....................................................................................................................21  
2.3. Benefit/Risk Assessment  ................................................................................................22  
2.3.1.  Risk Assessment  .............................................................................................................22  
2.3.2.  Benefit Assessment  .........................................................................................................22  
3. Objectives and Endpoints  ............................................................................................23  
4. Study Design ..................................................................................................................25  
4.1. Overall Design  ................................................................................................................25  
4.2. End of Study Definition  ..................................................................................................26  
5. Study Population  ...........................................................................................................27  
5.1. Inclusion Criteria  ............................................................................................................27  
5.2. Exclusion Criteria  ...........................................................................................................27  
5.3. Recruitment and Engagement  .........................................................................................27  
5.3.1.  Participant Recruitment ..................................................................................................27  
5.3.2.  Participant Engagement  ..................................................................................................27  
5.3.3.  Participant Randomization Process  .................................................................................28  
5.4. Screen Failures  ................................................................................................................28  
5.5. Enrollment  ......................................................................................................................29  
6. Study Drug(s)  ................................................................................................................30  
6.1. Repurposed Medication Treatments  ...............................................................................30  
6.2. Placebo  ............................................................................................................................30  
6.3. Study Drug Accountability  .............................................................................................30  
6.4. Concomitant Therapy  .....................................................................................................30  
6.5. Intervention After the End of the Study ..........................................................................30  
7. Participant Withdrawal/Termination and Study Termination  ................................31  
7.1. Participant Withdrawal/Termination  ..............................................................................[ADDRESS_1011238] to Follow -up............................................................................................................31  
8. Study Assessments and Procedures .............................................................................33  
8.1. Schedule of Events ..........................................................................................................34  
8.1.1.  Screening .........................................................................................................................35  
8.1.2.  Intervention Period  ..........................................................................................................35  
8.1.3.  Follow -up Period  ............................................................................................................36  
8.1.4.  Final Visit ........................................................................................................................36  
8.2. Clinical Assessments ......................................................................................................37  
8.3. Quality of Life Questionnaires  .......................................................................................38  
9. Safety Assessments  ........................................................................................................39  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011239] (ADE) and Unanticipated A dverse 
Device Effect (UADE)  ....................................................................................................[ADDRESS_1011240] ................................................................................................43  
9.2. Unanticipated Problem (UP) and Terminations ..............................................................43  
9.2.1.  Definition of Unanticipated Problem  ..............................................................................43  
9.2.2.  Reporting of an Unanticipated Problem  .........................................................................43  
10. Statistical Considerations  .............................................................................................44  
10.1.  Statistical Hypotheses  .....................................................................................................44  
10.1.1.  Primary Hypothesis  .........................................................................................................44  
10.2.  Sample Size Determination  ............................................................................................44  
10.3.  Randomization ................................................................................................................44  
10.4.  Blinding  ..........................................................................................................................45  
10.5.  Populations for Analyses  ................................................................................................45  
10.6.  Statistical Analyses  .........................................................................................................45  
10.6.1.  General Considerations  ...................................................................................................46  
10.6.2.  Statistical modeling  .........................................................................................................46  
10.6.3.  Assessing Effectiveness (Primary Objective)  .................................................................46  
10.6.4.  Interim Analyses (IA), Early Stoppi[INVESTIGATOR_007], and Type -I Error Control  .................................46  
10.6.5.  Sensitivity and Supplementary Analyses  ........................................................................48  
10.6.6.  Differential Treatment Effects and Subgroup Analyses  .................................................48  
10.6.7.  Secondary Clinical Endpoint  ..........................................................................................49  
10.6.8.  Exploratory Analysis  ......................................................................................................49  
10.6.9.  Adherence and Retention Analysis  .................................................................................49  
10.7.  Interim Reporting  ............................................................................................................50  
10.8.  Independent Data Monitoring Committee (IDMC)  ........................................................[ADDRESS_1011241] (IRB)  ...................................................................................[ADDRESS_1011242] Keepi[INVESTIGATOR_007]  ...........................................................................55  
12.1.  Data Collection and Management Responsibilities  ........................................................55  
12.2.  Study Records Retention  ................................................................................................55  
12.3.  Protocol Deviations .........................................................................................................55  
12.4.  Publication and Data Sharing Policy  ..............................................................................55  
13. Study Leadership  ..........................................................................................................57  
14. Summ ary of Changes ....................................................................................................58  
15. References  ......................................................................................................................65  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 6 16. Appendix A (Enrollment Closed 04FEB2022) – Ivermectin 
[ADDRESS_1011243]  ...............................................................................................74  
17. Appendix B (Enrollment Closed 27May2022) – Fluvoxamine 
Maleate  ...........................................................................................................................[ADDRESS_1011244]  ...............................................................................................81  
18. Appendix C (Enrollment Closed 08FEB2022) – Fluticasone Furoate  ...........................................................................................................................[ADDRESS_1011245]  ...............................................................................................86  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 7 18.6.  Safety Reporting for Fluticasone Furoate  .......................................................................86  
19. Appendix D – Ivermectin [ADDRESS_1011246]  ...............................................................................................88  
20. Appendix E – Fluvoxamine Maleate [ADDRESS_1011247]  ...............................................................................................91  
21. Appendix F – Montelukast  ...........................................................................................[ADDRESS_1011248]  ...............................................................................................96  
 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011249]  
KO Knockout  
LPS Lipopolysaccharide  
MAOI  Monoamine Oxidase Inhibitors  
mITT  Modified Intention to Treat  
MOP  Manual of Procedures  
NCATS  National Center for Advancing Translational Sciences  
NIH National Institute of Health  
OCD  Obsessive Compulsive Disorder  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 9 OHRP  Office for Human Research Protections  
OR Odds Ratio  
PCORI  Patient -Centered Outcomes Research Institute  
PCR  Polymerase Chain Reaction  
PHI Personal Health Information  
PHQ  Patient Health Questionnaire  
PI [INVESTIGATOR_436307] S uccess  
PROMIS  Patient -reported Outcomes Measurement Information System  
QOL Quality of Life  
RNA  Ribonucleic Acid  
RRT  Renal Replacement Therapy  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS -CoV -1/2 Severe Acute Respi[INVESTIGATOR_696] S yndrome Coronavirus 1/[ADDRESS_1011250]  
UP Unanticipated Problems  
US [LOCATION_002]  
WT Wildtype  
  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 10 Table of Figures  
Figure 1: ACTIV -6 Study Schema  ............................................................................................... 19 
Figure 2. ACTIV -6 Interim Analysis Schem a .............................................................................. 20 
Figure 3: Operational Structure Diagram  ..................................................................................... 57 
Figure 4: Survival curve of WT and S1R KO mice  ...................................................................... 79 
Figure 5:  Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early COVID -
19................................................................................................................................................... 80 
Figure 6:  Summary of study results for the prospective, nonrandomized observational cohort 
study with fluvoxamine in participants diagnosed with COVID -19. ........................................... 80 
Figure 7. Probability of efficacy for the primary outcome in the ITT and mITT populations of 
TOGETHER ................................................................................................................................. 90 
 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011251] of Tables  
Table 1: Schedule of Events  ......................................................................................................... 34 
Table 2: ACTIV -6 Sample Size Estimates and Power  ................................................................. 44 
Table 3: Ivermectin Adverse Event Table for Doses ≥  300 µ g/kg ............................................... 70 
Table 4: Ivermectin 400 Dosing Schedule  .................................................................................... 72 
Table 5. Fluvoxamine Adverse events occurring in 10- week studies of adult OCD or depression
....................................................................................................................................................... 75 
Table 6. Fluvoxamine Adverse events that occurred in COVID -19 study participants receiving 
300 mg/day for 15 days................................................................................................................. 76 
Table 7. Fluticasone Adverse reactions that occurred in ≥3% of adults and adolescents with 
asthma in a [ADDRESS_1011252] sodium adverse reactions occurring at a higher incidence than placebo, in ≥1% of adults and adolescents ≥ [ADDRESS_1011253]  ...................................................................... 95 
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 12 1. Protocol Summary  
1.1. Synopsis  
 
Title  ACTIV- 6: COVID- 19 Outpatient Randomized Trial to Evaluate 
Efficacy of Repurposed Medications  
Clinical study phase  III 
Rationale  Coronavirus Disease 2019 ( COVID- 19) is caused by a novel 
coronavirus, severe acute respi[INVESTIGATOR_6507] 2 
(SARS -CoV -2), that first emerged in December  [ADDRESS_1011254] been  made for treatment 
of COVID- 19 and vaccination for prevention of SARS -CoV- 2 
infection. However, the pandemic continues to evolve with new variants and surges of infections in different regions of the world , 
requiri ng an ongoing evidence -generating  clinical trial platform, in 
particular for the treatment of COVID -19 in the outpatient setting. 
This platform protocol can serve as an evidence generation system for prioritized drugs , repurposed from other  Food and Drug 
Administration (FDA)  indications with an established safety record  
in humans  and preliminary data  of efficacy.  The ultimate goal is to 
evaluate if repurposed medications can make p articipants feel better 
faster and reduce death and hospi[INVESTIGATOR_059].  
Primary Objective  • To evaluate the effectiven ess of repurposed medications [(study 
drug(s)]  in nonhospi[INVESTIGATOR_740085]- 19 
Secondary Objectives  • To evaluate the clinical outcomes  in participants in a study drug 
arm versus those in the placebo arm  
• To describe symptom resolution  in participants in a study drug 
arm versus those in the placebo arm  
• To describe the quality of life (QOL) in participants in a study drug arm versus those in the placebo arm  
• To compare illness severity trajectories in participants in a study drug arm versus those in the placebo arm  
Exploratory Objectives  • To describe long- term COVID- 19-related symptoms in 
participants in a study drug arm versus those in the placebo 
arm  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011255] of care. Each 
study drug appendix describes a different study drug and matching placebo. The following arms will be included in each 
study appendix:  
• Study Drug Arm : repurposed medications (see 
Appendices ) 
• Placebo Arm: placebo control  
While each appendix describes  the placebo that matches the 
study drug, for comparative analysis the control group will 
comprise eligible , concurrent ly enrolled participants from all 
study arms  who were assigned to placebo.  
Study Design This study is a platform  protocol designed to be flexible so that 
it is suitable for a wide range of settings within healthcare 
systems and in community settings where it can be integrated 
into routine COVID -19 testing programs and subsequent 
treatment plans. Th is platform  protocol will enroll participants in 
an outpatient setting with a confirmed positive  polymerase chain 
reaction (PCR ) or antigen test for SARS -CoV- 2. Each appendix 
will describe a repurposed medication ( study drug)  to meet the  
protocol objectives.  
When only one  study drug/appendix  is under study, allocation 
between study drug and placebo will be 1:1. If multiple study 
drugs/appendices  are under study, participants will also  be 
randomized among the study drugs  for which eligibility is 
confirmed. Since the route of administration of each study drug may differ, the placebos may also differ. To achieve blinding 
and an equitable randomization probability, a  two-step 
randomization process will be used.  
In the first step, the participant will be  randomized m :1 active  
study drug to placebo, where m  is the number of active study 
drugs  for which the participant is eligible  (note, if the same 
study drug is tested at multiple  doses, each dose will count as 
one study drug) . Then, participants  will be  randomized among 
the m study drugs  for which they are eligible. Participants will 
carry their ‘study drug’ versus ‘placebo’ randomization with them into the s tudy drug appendix. In this way, a participant  
allocated to placebo who is randomized to s tudy drug A will be 
given the placebo that matches s tudy drug A. This achieves 
equal probability of exposure among the placebo and active 
study drugs for which the participant is eligible , and equitable 
distribution among all study arms  for which a participant is 
eligible.  Sites will be informed to which study drug appendix  the 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 14 participant is  randomized , but not whether they are allocated to 
the study drug arm  or placebo arm within that appendix .  
For analysis, concurrent placebo participants who were eligible 
for the study  drug appendix will be pooled. This will result in 
approximately a 1:[ADDRESS_1011256] of care, the active study drug arm may serve 
as a concurrent placebo for other study drugs.  
Each study drug appendix will go through Screening Interim 
Analyses to assess efficacy /futility  prior to evaluation of the 
primary objective. This Screening Interim Analysis provides an 
innovative approach to evaluate the potential for repurposed 
drugs to reduce symptom burden and prevent disease 
progression in the outpatient setting at various points throughout enrollment. 
Participants will receive complete supply of repurposed 
medication (study drug) or placebo with length of treatment and 
amount of study drug/placebo depending on the  study drug 
appendix and arm  to which they are randomize d. 
This s tudy is designed so that it can be done completely 
remote ly. However, screening and enrollment may occur in - 
person at sites and unplanned s tudy visit s may occur in- person  
or remotely , as deemed appropriate by [CONTACT_436351] . Participants will be on -study for 120 days
1, during 
which they will complete various questionnaires.  
Population  Up to 15,000 adults   
Study Duration 24 months  
Study Location Up to 280 sites  
Inclusion Criteria  1. Completed Informed Consent  
2. Age ≥  30 years old  
3. Confirmed SARS -CoV- 2 infection (or reinfection) by [CONTACT_436352] 10 
days of s creening  
4. Two or more c urrent symptoms of acute infection for ≤  7 days . 
Symptoms include the following:  fatigue, dyspnea, fever, cough, 
                                                 
1 120 days on -study was implemented after closing arms Ivermectin 400, Fluvoxamine Maleate, and Fluticasone 
Furoate; in those arms, participants were on study for 90 days.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 15 nausea, vomiting, diarrhea, body aches , chills, headache, sore 
throat, nasal symptoms, new loss of sense of taste or smell . 
Exclusion Criteria  1. Current or recent (within 10 days of screening) hospi[INVESTIGATOR_198627]- 19 infection  
2. Current or planned participation in another interventional trial to 
treat COVID -19, at the discretion of the study principal 
investigator (PI)  
3. Current or recent use (within the last 14 days ) of study drug or 
study drug/device combination*  
4. Known allergy/sensitivity or any hypersensitivity to 
compone nts of the study drug or placebo* 
5. Known contraindication(s)  to study drug including prohibited 
concomitant medications (see Appendices) * 
*If only one study drug appendix  is open at the time of enrollment. 
If multiple study drug appendices  are open, a participant may opt -
out of any study drug appendix or be excluded from any  study drug 
appendix based on contraindications listed in the s tudy drug 
appendix , current use of st udy drug, or known 
allergy/sensitivity/hypersensitivity and still remain eligible for the 
remaining study drug appendi ces. 
Sample Size Considerations  This study will enroll up to 15,000 adults, depending on the number of study drug appendice s that are added and adjustments 
to sample size depending on the data.  
An estimated sample size of approximately 1,200 participants 
per study drug appendix  is expected  to be sufficient  to conclude  
whether there is meaningful evidence of benefit. A  screening  
interim analyses ( sIA) will occur at n=300 and n=600 to inform 
termination of the arm, continuation of enrollment, or transition 
to assessment of the primary objective.  Interim analyses (IAs) of 
the primary  objective are planned at n=300, n=600 and n=900.  
As described in the statistical analysis plan  (SAP) , the type I 
error for the primary objective  is controlled at <  0.05. 
General Statistical 
Consideration for Primary Analysis  The primary objective of effectiveness will be determined based on the endpoints of hospi[INVESTIGATOR_059]/ death  or time to recovery  over 28 
days, the choice of which will be specified per appendix. The 
choice will  be documented prior to interim analyses or prior to 
unblinding. The choice will be guided by [CONTACT_740100], as well 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011257] for this platform  (symptoms, 
hospi[INVESTIGATOR_059] , and mortality)  are collected  using a web-assisted 
symptom di ary according to the schedule in Table 1. Symptoms 
will be graded on an ordinal scale  as none, mild, moderate, or 
severe.  
The risk difference in hospi[INVESTIGATOR_436309]. Time t o recovery, measured as 
the time to achieving three consecutive days of self -reported 
symptom freedom , will be  used to draw conclusions about symptom 
burden.  
The primary analysis will be implemented separately for each study 
drug, where the matching placebo arm will consist of concurrently randomized participants that meet the inclusion and exclusion 
criteria for that study drug appendix . A modified intention to treat 
(mITT)  approach will be used for primary analyses ; all participants  
who receive study drug will be included as assigned. It is possible  
that the delivery of medications (placebo or study drug) does not 
occur  (failure of delivery, participant death, or participant 
withdrawal); this will  result in exclusion of the participa nt for the 
mITT analysis. All available data will be used to compare each 
study drug versus placebo control, regardless of post -randomization 
adherence to study protocols.  
Independent Data Monitoring 
Committee ( IDMC)   Frequent IDMC  reviews will be conduc ted to ensure the safety of 
study participants and evaluate the accumulating endpoint data by [CONTACT_1570]. Regular IDMC meetings will monitor the 
following parameters at a minimum:  
• Recruitment progress  
• Enrollment overall and by [CONTACT_12125]  
• Adherence, ret ention, and status of data collection  
• Serious adverse events  
• Assessment for futility  
• Probability for benefit across endpoints  
Interim Analysis  Interim analyses  (IA) will be performed per s tudy drug appendix , 
after approximately every 300 participants  (~150 in study drug arm 
and ~ 150 in placebo arm)  have completed the Day [ADDRESS_1011258] regardless 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 17 of final study d rug arm allocation . The following decision 
thresholds will be checked during IA (s): 
i) Screening IA (n=300):  
a. The study drug is found to have benefit (efficacy). 
Study drug appendix will proceed to primary objective IA at n=300. Note: this is also a check for harm as all assessments are two -tailed.  
b. The study drug is not found to have benefit, 
enrollment continues in the study drug appendix and 
sIA is repeated at n=600.  
ii) Screening IA (n=600):  
a. It would be futile to atte mpt to show a benefit of the 
study drug based on the predicted probability of 
success (PPOS)  and other factors . The s tudy drug 
appendix will be terminated.  
b. Futility is not determined.  Study drug appendix will 
proceed to primary objective IA at n=600. 
iii) Prim ary Objective IA (n= 300): if  the criteria for 
proceeding to the primary objective are met  when 
n=300, a  primary objective  IA will be conducted for the 
primary objective when n=300. T he following decisions 
will be assessed:  
a. The study drug is found to have benefit (efficacy) , 
the study drug appendix will be terminated as the 
primary endpoint has been met.  
b. It would be futile to attempt to show a benefit of the 
study drug based on the PPOS and other factors . The 
study drug appendix will be terminated.  
c. Efficacy/futility is undeterminable , enrollment will 
continue in the study drug appendix and the primary 
objective IA will be assessed at n=600 .  
iv) Primary Objective IA (n= 600, 900):  if the criteria for 
proceeding to the primary objective IA are met when 
n=600 or n=900, a  primary objective  IA will be 
conducted. The following decisions will be assessed:  
a. The study drug is found to have benefit (efficacy) , 
the study drug appendix will be  terminated as the 
primary endpoint has been met.  
b. It would be futile to attempt to show a benefit of the 
study drug based on the PPOS and other factors . The 
study drug appendix will be terminated.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 18 c. Efficacy/futility is undeterminable,  enrollment will 
conti nue in the study drug appendix and the primary 
objective  will be assessed after another [ADDRESS_1011259] been enrolled, or until n=1200.  
A posterior probability of meaningful benefit  for a  study d rug in 
comparison to the  placebo control of greater  than the appendix-
specified threshold  will result in a declaration of  overall  superiority . 
A PPOS when n= [ADDRESS_1011260] of either the planned 
accrual or predicted accrual at study clo sure.  
 
  
 
  
 
  
 
  
 
  
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 19 1.2. Schema  
 
 
Figure 1: ACTIV- 6 Study Schema  

CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 20  
Figure 2. ACTIV- 6 Interim Analysis Schema  

CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 21 2. Introduction 
2.1. Study Rationale  
Severe acute respi[INVESTIGATOR_6507] 2  (SARS -CoV- 2) is a novel betacoronavirus  that 
first emerged in  December [ADDRESS_1011261] to the number of cases and overall mortality. [1, 2]  The clinical disease 
related to  SARS -CoV- 2 is referred to as Coronavirus Disease 2019 ( COVID- 19). Since  2020, 
advances have been made for treatment of COVID -19 and vaccinations  for prevention of SARS -
CoV- 2 infection, through emergency use authorization or  FDA approval .[3-8] However, the 
pandemic continues to evolve with new variants and surges of infections in different regions of 
the world , requiring an ongoing evidence- generating platform, in particular for the  treatment of 
COVID- [ADDRESS_1011262] and preliminary evidence of clinical efficacy 
for the treatment of COVID -19. The ultimate goal is to evaluate if repurposed medications can 
make participants feel better faster and reduce death and hospi[INVESTIGATOR_059].  
2.2. Background  
In December  2019, numerous patients in Wuhan, China were diagnosed with pneumonia caused 
by [CONTACT_88529]. By [CONTACT_36466] 7, 2020, Chinese scientists had isolated SARS -CoV- 2. This is 
a novel betacoronavirus closely related to severe acute respi[INVESTIGATOR_6507]  1 
(SARS -CoV -1).[2]  In the subsequent months the spread of the virus led to  a global pandemic. 
As of February 7, 2022 there were approximately  395,540,912 confirmed COVID- 19 cases 
resulting in  5,741,726 deaths worldwide.[1]  
The virus continues to spread despi[INVESTIGATOR_740086], vaccination 
campaigns/requirements,  and travel restrictions. COVID- 19 vaccinations continue to be 
distributed and administered  globally;  however, new SARS -CoV- 2 strains continue to emerge, 
with potential for reduced  monoclonal antibody therapeutic and  vaccine efficacy. [9] As new 
strains have emerged that confirm t ransmission , infection, and even severe disease after 
vaccination is possible , highlighting the need to establish treatment regimens despi[INVESTIGATOR_88481].  Furthermore, acceptance and uptake of booster shots has been lower than uptake  of 
the initial vaccination series, further justifying the need for safe and effective therapi[INVESTIGATOR_014].  Thus, 
there remains a need to identify safe and efficacious treatments that can be administered in the 
outpatient setting.  
As of February 2022, multiple clinical trials have been reporte d, providing guidance to clinical 
providers on management of COVID -19, particularly in the hospi[INVESTIGATOR_6885]. Various drugs, 
including monoclonal antibodi es and antivirals, have been authorized or approved by [CONTACT_941] F DA 
for use in the inpatient  and outpatient  setting  for treatment of COVID -19.  Multiple repurposed 
immunomodulatory agents are clinically used for  the treatment of severe COVID -[ADDRESS_1011263] been reported to i mprove clinical disease and 
in some cases, mortality .[10, 11]  Few of these are FDA approved and few are therapi[INVESTIGATOR_740087].    
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 22 2.3. Benefit/Risk Assessment  
The risks for participation in this study include taking study drug (see Appendices)  and loss of 
confidentiality . There may be some benefit to the participant if the therapy is effective against 
COVID-19. 
2.3.1. Risk Assessment  
Loss of confidentiality risks : Ther e is a potential risk of loss of confidentiality. Every effort will 
be made to protect the participant’s confidential medical information, but this cannot be 
guaranteed. Clinical information will not be released without written permission of the  
participan t, except as necessary for monitoring by [CONTACT_1201], FDA, National Institutes of Health 
(NIH), Office for Human Research Protections ( OHRP ), other local, US, and international 
regulatory authorities/entities as part of their duties.  
Risk lowering measures: Study procedures to manage and minimize risks include careful 
selection of the participants and monitoring over time to check on participants ’ health. 
Additional guidance to manage any risks  or any change to the risk to the participant  based on 
emerging data will be provided to the study teams, as needed. In addition, an independent 
Independent Data Monitoring Committee  (IDMC) will monitor safety of the participants 
throughout the study.  
2.3.2. Benefit Assessment  
Participants who randomize to a study drug arm  may benefit from study drug administration.  
There is no direct benefit to participants randomized to the placebo arm  apart from participating 
in generating evidence that may ultimately support treatment  for SARS -CoV-2 infection. In 
addition, they will benefit from involvement with the team following their health status during 
the study. The knowledge gained will be a benefit to others in the future.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 23 3. Objectives and Endpoints  
Objectives  Outcome Measurement s Reported Endpoints 
Primary    
To evaluate the 
effectiveness of repurposed 
medications [(study drug(s)] 
in nonhospi[INVESTIGATOR_436313]-19 • Hospi[INVESTIGATOR_740088] 28 
• Time to recovery  over [ADDRESS_1011264].  
Secondary   
To evaluate the clinical outcomes in participants in 
a study drug arm versus 
those in the placebo arm  • COVID Clinical 
Progression Scale on Day 
7, Day 14, and Day 28 (see Section 8.2) 
• Mortality through Day 28 
• Hospi[INVESTIGATOR_059], urgent care visit, emergency 
room visit through Day 28 The following model-assisted endpoints will be 
reported for the COVID Clinical Progression Scale : 
• The OR describing the 
overall difference in 
clinical progression  
• The OR describing the 
difference in clinical 
progress ion at each 
measured time point 
• The overall risk difference for hospi[INVESTIGATOR_740089] : 
• The overall risk difference 
for any of urgent care, 
emergency care, 
hospi[INVESTIGATOR_740090] -6 Protocol [v6.0] 
 
 24 • Time to first urgent care, 
emergency care,  
hospi[INVESTIGATOR_30059]  
• Risk and time to event for 
each component of the composite  
To describe symptom resolution in participants in 
a study drug arm versus 
those in the placebo arm  Symptom resolution, defined as  three co nsecutive days without 
symptoms  Time to symptom resolution 
To describe the quality of life (QOL) in participants in a study drug arm versus 
those in the placebo arm  Modified Patient-Reported 
Outcomes Measurement Information System (PROMIS)-
29 at baseline, Day 7, Day 14, 
Day 28, Day 90, and Day 120
2 
Follow-up • Overall common odds ratio 
(cOR)  
• Odds ratios ( cORs) specific 
to days 7, 14, 28, 90, and 120
2 
• Mean difference in QOL 
scores at each time point  
To compare illness severity trajectories in participants in 
a study drug arm versus those in the placebo arm  Ordinal outcome including 
symptom severity, 
hospi[INVESTIGATOR_059] , and death 
measured daily for 14 days • Difference in mean time 
unwell 
• Mean days of benefit  
Exploratory    
To describe long- term 
COVID-19- related 
symptoms in participants in a study drug arm versus 
those in the placebo arm  Symptom occurrence, type, and severity at Day 90 or Day 120
2 
Follow-up 
 Directly measured mean and median symptom count and QOL score at Day 90 or Day 
120
2 in study drug arm(s) 
versus placebo. 
                                                 
[ADDRESS_1011265] and Fluvoxamine Maleate 100; Day 90  was the final follow -up 
day for Ivermectin 400, Fluvoxamine Maleate, and Fluticasone Furoate  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 25 4. Study Design 
Refer to Section 1.2 for the Study Schema.  
This study includes an innovative screening approach using sIA s to make decisions about  
droppi[INVESTIGATOR_740091], or to accelerate study of potentially effecti ve agents . Each 
study drug appendix will go through sIAs to assess efficacy /futility  prior to evaluation of the 
primary objective. This  sIA provides an innovative approach to evaluate the potential for 
repurposed drugs to reduce symptom burden and prevent disease progression at various points 
throughout enrollment  in a broad population.  
4.1. Overall  Design  
This study is a platform  protocol designed to be flexible so that it is suitable for a wide range of 
settings within healthcare systems and in community settings where it can be integrated into 
routine COVID -19 testing programs and subsequent treatment plans. The platform  protoco l will 
enroll participants  with mild to moderate COVID -19 in an outpatient setting with a confirmed 
positive polymerase chain reaction ( PCR)  or antigen test  for SARS -CoV- 2 infection . Each 
appendix will describe a repurposed medication ( study drug arm) that is sized to meet the master 
protocol objectives.  
Participants will be randomized to one of the study drug appendices that are actively enrolling at 
the time of randomization. Study drug appendices  may be added or removed according to 
adaptive design and/o r emerging evidence. When there  are multiple study drug a ppendices  
available, randomization will occur based on appropriateness of each drug for the participant  as 
determined by [CONTACT_88531] . Each participan t 
will be required to randomize to at least one study drug versus placebo. The probability of 
placebo to treatment will remain the same regardless of eligibility  decisions.   
Eligible participants will be randomized (1:1), in a blinded fashion, to either the study drug 
arm or placebo arm  in addition to standard of care , when one active drug is on the platform or 
when a participant is only eligible for one of the active drugs on the platform . As additional 
study drug appendices  are added, the randomization will be altered to leverage placebo data 
across arms.  If a study drug is offered at two doses, each dose will be treated  as separate study 
arm. If a participant is eligible for  [ADDRESS_1011266] a 1:[ADDRESS_1011267] a 2:1 chance of receiving an active study drug, for 3 arms it is 3:1, for 4 arms it is 4:1, and so on. This is because each 
participant assigned to a placebo group is shared among all appendices, and the goal is that 
within appendices the allocation probability to study drug versus placebo is 1:1.  Participants 
will receive a complete supply of repurposed medication (study drug)  or placebo with the 
quantity depending on the study drug/placebo to which they are randomize d. 
All study visits are designed to be remote. However, screening and enrollment may occur in -
person at sites and unplanned study visit s may occur in- person  or remotely , as deemed 
appropriate by [CONTACT_88532] . Participants will be asked to complete 
questionnaires and report  safety events during the study, according to Table 1. Participants will 
be prompted by [CONTACT_88533], as necessary .  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011268] completed the study if he/she has completed the Long- term 
Follow -up assessments at [ADDRESS_1011269] and Fluvoxamine Maleate 100; Day 90 was the final follow -up 
day for Ivermectin 400, Fluvoxamine Maleate, and Flu ticasone Furoate  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 27 5. Study Population  
All Eligibility Criteria will be obtained per participant.   
5.1. Inclusion Criteria  
1. Completed Informed Consent  
2. Age ≥ 30 years old  
3.   Confirmed SARS -CoV -2 infection (or reinfection)  by [CONTACT_740101] 10 days of s creening  
4. Two or more c urrent symptoms of acute infection for ≤ 7 days . Symptoms include the 
following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches , chills, 
headache, sore throat, nasal symptoms, new loss of sense of taste or smell  
5.2. Excl usion Criteria  
1. Current or recent (within 10 days of screening) hospi[INVESTIGATOR_436318]- 19 infe ction  
2. Current or planned participation in another interventional trial to treat COVID -19, at the 
discretion of the study principal investigator (PI)  
3. Current or  recent  use (within the last 14 days ) of study drug or study drug/device 
combination*  
4. Known allergy/sensitivity or any hypersensitivity to components of the study drug or 
placebo * 
5. Known contraindication(s)  to study drug including prohibited concomitant medications 
(see Appendices) * 
*If only one study drug appendix is open at the time of enrollment. If multiple study drug appendices are open, a participant may opt -out of any study drug appendix or be 
excluded from any study drug appendix based on contraindications listed in the study drug appendix , current use of study drug, or known aller gy/sensitivity/hypersensitivity 
and still remain eligible for the remaining study drug appendices.  
5.3. Recruitment and Engagement  
5.3.1. Participant Recruitment 
Participants who are eligible based on positive SARS -CoV- [ADDRESS_1011270] will be 
identified by [CONTACT_740102] -identify to a central study hotline (s) and be referred to 
the closest site. Site investigators, or their designee, may  contact [CONTACT_88537].  
5.3.2. Participant Engagement  
Participants will be engaged in the study through multiple channels. This includes , but is not 
limited to , ongoing participation in other registries partnering with ACTIV or healthcare systems.  
Additionally, participant engagement will include:  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 28 • compensation for participants who complete the Day 90 or 1204 Final Visit;  
• creating a study- wide ACTIV- 6 Advisory Group;  
• developi[INVESTIGATOR_88488] -centered approaches that recognize the needs and preferences of 
COVID- 19 survivors locally and nationally; and  
• multifaceted approaches that combine engagement tool s, leverage the online system , use 
of social media, and representative COVID- Participants.  
5.3.3. Participant Randomization Process  
This trial is a double -blind, placebo -controlled trial. Pa rticipants and investigators will be  
blinded. A participant who is eligible for m  study drug arms /appendices  will be randomized m:1 
study drug to placebo ( Figure 1). Th e participant will then be randomized with 1/m  probability 
to each of the study drug appendices . A participant entering a study drug appendix carries their 
study drug or placebo designation with them and will get either the study drug or matching 
placebo. Participants who receive placebo will be pooled across study drug arms for those study 
drug arms /appendices  that the participant is eligible. This reduces overall sample size by 
[CONTACT_88538] a 1:1 allocation to study 
drug or placebo within an appendix. Randomization sequences will not be pre -generated. Given 
the adaptive nature of the trial and the unknown number of study drug appendice s, arm 
assignment will be implemented at the time of confirming eligibility for randomization  using a 
random number generator. The participant eligibility criteria will be checked for each study  drug 
appendix, and the randomization probabilities will be set. The two step procedure will then 
occur, and the assignment to both study drug appendix and study drug versus placebo will be 
made. The participant and study teams will know w hich s tudy drug a ppendix the pa rticipant is 
allocated to , but will be blinded to study drug versus placebo because they will be matching.  
The participant, treating clinicians, and study personnel will remain blinded to study drug versus 
placebo  assignment until after the database is lo cked and blinded analysis is completed. Only the 
biostatistical team who is preparing closed IDMC interim reports will be unblinded. Specifically, 
study drug/placebo will be dispensed with packaging and labelling that would blind treatment 
assignment. Unbl inding will occur only if required for participant  safety or treatment at the 
request of the treating clinician . Refer to the Manual of Procedures (MOP) for further details.  
5.4. Screen Failures 
Screen failures are defined as participant s who consent to participate in the clinical study, who 
fulfill inclusion and exclusion criteria, but are not subsequently randomized. Screen failures also include participants who consent, then on review by [CONTACT_779], are found to be ineligible for the 
study. A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure participant s to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from r egulatory au thorities.   
Individuals who are considered screen failures may not be re -screened.  
                                                 
[ADDRESS_1011271] and Fluvoxamine Maleate 100; Day 90 was the final follow -up 
day for Ivermectin 400, Fluvoxamine Maleate, and Fluticasone Furoate  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 29 5.5. Enrollment  
Participants who are randomized and receive study drug/placebo will be considered enrolled. 
Participants who are randomized, but do not receive study drug/placebo for any reason ( e.g., 
study drug lost in the mail , death prior to receipt of study drug, participant withdrawal prior to 
receipt of study drug), will not be considered enrolled on the study and will be identified as randomized not enrolled.  
Receipt of study drug will be defined as evidence that the study drug was delivered to the 
address of record.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 30 6. Study Drug (s) 
6.1. Repurposed Medication Treatments  
See Appendices  
6.2. Placebo  
See Appendices  
6.3. Study Drug Accountability  
Use of study drug will be tracke d via the online system , call center , or sites . Participants will 
dispose of any unused study drug as they would normally when stoppi[INVESTIGATOR_007] a medication. 
6.4. Concomitant Therapy  
Select concomitant medications of interest  that the participant is receiving at the time of 
enrollment or receives during the course of the study  will be recorded along with dosing 
information. Select concomitant medications of interest include the following  and will be 
verified at each remote visi t by [CONTACT_51015] : 
• Any t herapeutics that is thought to have potential  or purported COVID activity  including 
hydroxychloroquine  
• Antibiotics  
• Antifungals  
• Antiparasitic  
• Antivirals including HIV protease inhibitors and ribavirin  
• Immunosuppressan ts including steroids  
• Angiotensin -converting -enzyme (ACE)/angiotensin II receptor blockers 
(ARB) /angiotensin receptor neprilysin inhibitor ( ARNI ) 
• Statin 
• Anticoagulants and antiplatelets  
• COVID- 19 vaccine (before, during, or after study intervention)  
Refer to the MOP for more details on concomitant therapy. Refer to the appendices for 
contraindicated  medications for each of the study drugs.  
6.5. Intervention A fter the End of the Study  
No additional study drug will be provided to the participant following completion of the study.   
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 31 7. Participant Withdrawal/Termination and Study Termination  
7.1. Participant Withdrawal/Termination  
Participants will be followed until participant closeout, withdraw al of consent, or death. 
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons. This is expected to be uncommon.  
Those who request withdraw al from the study will be asked to continue on study follow -up with 
limited participation through the Final Visit (Section 8.1.4).  Limited participation may include a 
call(s) to assess safety  at study visits following withdrawal . 
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected befor e such a withdrawal of consent. 
7.2. Premature Termination or Suspension of the Study  
The study may  be temporarily suspended  or prematurely terminated if there is sufficient 
reasonable cause. Written notification will be provided documenting reason for study suspension 
or termination to the investigators, funding agency, and regulatory authorities , as appropriate . 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or eval uable  
• Determination of futility after a sufficient time has passed for accrual of the primary and 
secondary outcomes  
• Recommendation by [CONTACT_31849] 
7.3. Lost to Follow -up 
Participants will be asked for proxy contacts to assess vital status and/or other clinical eve nts, 
including safety, if a participant fails to provide the information. Provision of proxy information 
is not required for study participation. A participant will be considered lost to follow -up if he or 
she repeatedly fails to  complete study assessments/procedures  as outlined below  and neither the 
participant nor the participant’s  proxy can  be contact[CONTACT_9298].  
The following actions must be taken if a participant  fails to provide baseline  information, if he or 
she fail to complete daily symptom reporting by [CONTACT_88539]/placebo  (Day 2) , if he or she miss one  daily sympto m reporting  during Days 3 to 14, 
if he or she miss either the Day 14 or Day 28 Remote Visits , and/or he or she fail to complete the 
Day 90 and Day 1205 assessments:  
• The site or call center must attempt to contact [CONTACT_401634] c ounsel the participant  
on the importance of completing study assessments/procedures. 
                                                 
[ADDRESS_1011272] and Fluvoxamine Maleate 100; Day 90 was the final follow -up 
day for Ivermectin 400, Fluvoxamine Maleate, and Fluticasone Furoate  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 32 • The site or call center will contact [CONTACT_2299]’s proxy to assess vital status and/or 
other clinical or safety events.  
• The site or call center will attempt to collect all missing survey  responses.  
• Before a participant  is deemed lost to f ollow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635]  (where possible, three  telephone calls 
and, if necessary , a certified letter to the participant’s last known mailing address or 
local equivalent methods). These contact [CONTACT_21457] ’s research  record . 
• Online obituary search.    
• Should the participant  continue to be unreachable, they will be considered lost to 
follow -up.  
 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011273] be verified prior to randomization ( refer to the MOP for details ). Sites will be 
responsible for notifying the coordinating center for participant w ithdrawals, lost to follow -up, 
permanent cessation of study drug, study drug dose modifications  (if allowed, per Appendix) , or 
change in vital status. Data will be  collected directly from the participant and supported by 
[CONTACT_30219], as needed.  
  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 34 8.1. Schedule of Events   
 
Table 1: Schedule of Events  
 
                                                 
[ADDRESS_1011274] and Fluvoxamine Maleate 100; Day [ADDRESS_1011275] pregnancy listed as a contraindication for females of 
childbearing potential. Partici pants will self -report pregnancy using the Pregnancy Reasonably Excluded Guide.  
9 Review only during study drug/placebo administration if contraindicated medications provided for the study drug 
arm, per Appendix.  
10 Day 14 only.  
11 Daily symptom reporting; c ontinued daily beyond day 14 through day 28 until symptoms resolve for > 3 
consecutive days. All participants will complete symptom reporting on Days 21 and 28, regardless of symptom 
resolution.  
12 Day 7 and 14 only.  
13 Day 3, 7, and 14 only.  
14 Participant’s medical record will be reviewed to confirm Serious Adverse Events (SAEs), Unanticipated Adverse 
Device Events (UADEs) [as applicable], and Events of Special Interest (ESIs).   
 
 
 
 
 
 
 
 Screening  Intervention 
Period  Follow -up Period  
 Final 
Visit  Unplanned 
Study Visit  
Day 
Within 2 days of 
Day 1  
Day 1 
Days 2  - 14 
Day 15 - 20 
Day 21 ± 2  
Day 22 - 27 Day 28 + 5  
Day 90 + 5  
Day 120
6 + 
[ADDRESS_1011276] review  X 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 35 8.1.1. Screening  
The following events will occur at Screening : 
• Consent : Participants will be consented either via an e-consent process or paper process . 
The consent process should be done in accordance with local and central  IRB regulations. 
Phone consenting may be facilitated through the e- consent or paper process.  
• Demographic information will be collected including, but not limited to, age, sex, race, 
ethnicity , and  occupation  
• Eligibility criteria confirmation  by [CONTACT_88541] 
a paper process  
• Abbreviated medical history  
• Self-reported pregnancy, for women of childbearing potential ( only for enrollment in 
Study Drug Appendices that include pregnancy as a contraindication )  
• Concomitant therapy  
• Symptom reporting , daily  during screening period 
• QOL questionnaire 
• Randomization (see Section 5.3.3) 
8.1.2. Intervention Period  
The following events will occur during the Intervention Period, starting with receipt of study 
drug/ placebo : 
Day 1: 
• Receipt of study drug or placebo 
• Study drug self-admini stration  (see Appendices for specific study drug/placebo 
administration) 
• Concomitant therapy  
• Drug adherence questionnaire 
• COVID- 19 Outcomes  
• Symptom reporting  
• SAE , UADE (as applicable),  and ESI collection 
Days 2 – 14: 
• Study drug self- administration  (see Appendices for specific study drug/placebo 
administration) 
• Concomitant therapy, including contraindicated medications provided for the study drug 
arm, per Appendix, during study drug/placebo administration. 
• Remote visit  (Day 14 only) 
• Drug adherence questionnaire , daily  
• COVID- 19 Outcomes  (Day 7 and 14  only ) 
• Symptom reporting , daily  
• QOL questionnaire ( Day 7 and 14  only ) 
• At-home pulse oximetry readings ( Day 3, 7, and 14  only )  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 36 • SAE , UADE (as applicable),  and ESI collection 
8.1.3. Follow- up Period 
Day 15 – 20:  
• Symptom reporting, daily from Day [ADDRESS_1011277] not  yet reported three 
consecutive days of no symptoms. Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be followed daily. 
• SAE, UADE (as applicable),  and ESI collection 
Day 21 ± 2 days: 
• COVID- 19 Outcomes  
• Symptom reporting  
• SAE , UADE (as applicable),  and ESI collection 
Day 22 – 27:  
• Symptom reporting, daily from Day [ADDRESS_1011278] not  yet reported three 
consecutive d ays of no symptoms. Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be followed daily. 
• SAE , UADE (as applicable),  and ESI collection 
Day 28 + 5 days: 
• Remote visit  
• COVID- 19 Outcomes  
• Symptom  reporting  
• QOL questionnaire 
• SAE , UADE (as applicable),  and ESI collection 
Day 90 + 5 days:  
• COVID- 19 Outcomes  
• Symptom reporting  
• QOL questionnaire 
• SAE, UADE (as applicable), and ESI collection 
8.1.4. Final Visit  
Day 120 + 5 days15:  
• COVID- 19 Outcomes  
• Symptom reporting  
                                                 
[ADDRESS_1011279] an d Fluvoxamine Maleate 100; for Ivermectin 400, 
Fluvoxamine Maleate, and Fluticasone Furoate, day 90 is the final visit.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 37 • QOL questionnaire 
• SAE , UADE (as applicable),  and ESI collection 
8.2. Clinical Assessments  
Abbreviated Medical History : smoking status, estimated body mass index ( BMI )/obesity, pre -
existing underlying lung disease (e.g., chronic obstructive pulmonary disease, asthma, idiopathic 
pulmonary fibrosis), underlying immunosuppression (transplant, malignancy, human immunodeficiency virus ( HIV) , autoimmune disease), medical conditions that may increase risk 
of COVID-19 infections or complications (e.g., diabetes, cardiovascular disease, hypertension, chronic kidney disease) , venous thromboembolism, chronic liver disease , COVID- [ADDRESS_1011280]:  
 Concomitant medications of interest, including study drug 
specific contraindicated medications, will be collected. Refer to Section 6.[ADDRESS_1011281] and to the study drug specific appendices for contraindicated 
medications.  
Self-reported Pregnancy: Participants will be asked to self -report pregnancy, as needed, per 
Study Drug Appendix. The 3- item “Pregnancy Reasonably Excluded Guide” will be used to 
assess pregnancy at screening. The “Pregnancy Reasonably  Excluded Guide” uses traditional and 
World Health Organization criteria to exclude pregnancy via participant self -report.[12] Refer to 
the MOP for details.   
Re mote  Visit : Designated  study personnel will contact [CONTACT_88542] a phone call or 
other form of direct contact  (e.g., text or e -mail survey) in order to conduct study assessments, 
including, but not limited to, COVID-19 outcomes, drug adherence (at Day 14), and s afety 
events. A missed remote visit will be considered a protocol deviation  (non- major). If a 
participant misses a remote visit, site study staff should take immediate action to contact [CONTACT_2416], per Section 7.3 follow-up processes. Refer to the MOP for details.   
Drug Adherence: Adherence to the study drug administration schedule will be collected via the 
online system  and confirmed at the Day 14 r emote  visit. 
COVID-19  Outcomes: The COVID -19 outcomes for this trial are based on the World Health 
Organization’s Ordinal Scale for Clinical Improvement and  will be collected via the online 
system  and from the medical record .[13] The following outcomes will be assessed  as part of the 
COVID Clinical Progression  Scale:    
0. No clinical or virological evidence of infection  
1. No limitation of activities  
2. Limitation  of activities  
3. Hospi[INVESTIGATOR_057] , no oxygen therapy 
4. Hospi[INVESTIGATOR_057] , on oxygen by [CONTACT_88543] 
5. Hospi[INVESTIGATOR_057] , on non- invasive ventilation or high -flow oxygen 
6. Hospi[INVESTIGATOR_057] , on intubation and mechanical ventilation  
7. Hospi[INVESTIGATOR_057], on ventilation + additional organ support – pressors, RRT, ECMO 
8. Death  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 38 Symptom Reporting: Symptoms and symptom- related responses will be reported by [CONTACT_88544] . Additional symptom reporting may occur from the sites, as 
available. Each of pre- defin ed symptoms will be assessed on an ordinal severity scale of none, 
mild, moderate, and severe. The following symptoms will be collect ed:  
• Overall symptom burden 
• Fatigue 
• Dyspnea - shortness of breath or difficulty breathing at rest or with activity  
• Fever  
• Cough  
• Nausea  
• Vomiting  
• Diarrhea  
• Body aches 
• Sore throat 
• Headache  
• Chills 
• Nasal symptoms  
• New l oss of sense of taste or smell  
• Other COVID- related symptom   
At-home pulse oximetry measurements : Participants will provide pulse oximetry readings using 
a study- provided  FDA-approved pulse oximeter. Two consecutive pulse oximetry readings must 
be reported at each required time point. Day 3, 7, and Day 14 are study-required time points  for 
pulse oximetry readings. Participants can  report pulse oximetry readin gs at other times 
throughout the study, at their own discretion.   
8.3. Quality of Life Questionnaires  
The following QOL questionnaire will be used in this study: 
• Modified PROMIS -29: PROMIS  measures were developed through a collaborative 
process funded by [CONTACT_18121].[14] The PROMIS -29 consists of seven health domains with 
four 5- level items  associated with each and a pain intensity assessment using a 0 -10 
numeric rank. The seven health domains include physical function, fatigue, pain 
interference, depressive symptoms, anxiety, ability to participate in social roles and 
activities, and sleep disturbance.[15] The PROMIS -[ADDRESS_1011282] questions from each of the seven health domains, refer to the MOP for details.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011283] of a clinical trial. An AE can therefore be any change in clinical 
status, routine labs, x- rays, physical examinations, etc., that is considered clinically significant by 
[CONTACT_1704] .  
An SAE or serious suspected adverse reaction or serious adverse reaction  as determined by [CONTACT_88545]:  
• Death  
• Life-threatening AE (“life -threatening” means that the study participant was, in the 
opi[INVESTIGATOR_26335], at immediate risk of death from the reaction as it occurred and required immediate intervention)  
• Persistent or significant incapacity  or substantial disruption of the ability to conduct 
normal life functions  
• Inpatient hospi[INVESTIGATOR_1081]  
• Congenital abnormality or birth defect  
• Important medical event that may not result in one of the above outcomes, but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed in the above definition of serious event  
Hospi[INVESTIGATOR_5187] a preexisting condition th at did not worsen from 
baseline does not meet the definition of an SAE. Hospi[INVESTIGATOR_31561] a stay in the 
hospi[INVESTIGATOR_88489] [ADDRESS_1011284] (ADE) and Unanticipated Adverse Device Effect (UADE)  
For those repurposed medications that are a part of a combination product, which includes a drug 
and a device, the following additional definitions will apply.  
An ADE is an AE  related to the use of an investigational medical device. This includes any AE  
resulting from insufficiencies or inadequacies in the instructions for use, the deployment, the implantation, the installation, the operation, or any malfunction of the repurposed medical 
device. This also includes any event that is a result of a use error or intentional misuse.  
• Device malfunction – the failure of a  device to perform in accordance with the 
instructions for use or clinical investigative plan.  
• User error or intentional misuse – A device is used in a manner that is an act or omission 
of an act that results in a different medical device response than intended by [CONTACT_88546]. 
A UADE is any SAE  caused by, or associated with, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the investigational 
plan or applications (including a supplemental plan or application), or any other unanticipated 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 40 serious problem associated with a device that relates to the rights, safety, or welfare of 
participants.  
Unanticipated Adverse Device Effects (UADEs)  will include events meeting either A or B as 
stated below:  
A. Events meeting ALL of the following criteria:  
• Not included in the relevant appendices or Product Label  
• Related to the device per site PI [INVESTIGATOR_1238]/or IND sponsor  
• Serious (meets any of the following criteria):  
o Is life -threatening illness or injury  
o Results in permanent impairment of a body function or a body structure  
o Necessitat es medical or surgical intervention to prevent permanent 
impairment of a body function or a body structure  
o Results in hospi[INVESTIGATOR_059]  
o Led to fetal distress, fetal death, or congenital abnormality or birth defect  
o Led to death  
(Permanent means irreversible i mpairment or damage to a body structure or function, exclud ing 
trivial impairment or damage ). 
B. Any other unanticipated serious problem associated with the device that relates to the 
rights, safety, or welfare of participants.  
9.1.2. Collecti on Period for  AE and SA E Information  
Study participants (and their designated emergency proxies) will be instructed to report E SIs per 
appendix and Section 9.1.5, SAEs , and U ADEs  through their access t o the study’s online system . 
Each day for 14 days, the participant will be  asked to report on their symptoms and health state, 
including hospi[INVESTIGATOR_139074]/or other change in health condition. The assessments include 
specific questions pertaining to ESIs, as well as symptoms  and severity , health care visits, 
medications and a notification to the participant to contact [CONTACT_740103]. If the participant is still reporting symptoms at Day 14, they will continue to be 
assessed until they have experienced three consecutive days without symptoms, or until D ay 28, 
whichever is shorter. At Day 28, Day 90, and Day [ZIP_CODE], participants  will complete assessments. 
Safety reporting will be available to the participant continuously throughout the study, but will 
only be required at the aforementioned collection points.   
The daily and follow -up assessments, as described in the paragraph above,  will be monitored  and 
sites will be actively notified of events requiring review, including for reporting that meets criteria for ESIs , SAE s, or U ADEs . Refer to the MOP for details.  In addition, participants will be 
invited during assessments  to request contact [CONTACT_175964], or to report any unusual 
                                                 
[ADDRESS_1011285] and Fluvoxamine Maleate 100; Day 90 was the final follow -up 
day for Ivermectin 400, F luvoxamine Maleate, and Fluticasone Furoate  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011286] dose of  study medication (Day 2) or any day of missed assessments up to Day [ADDRESS_1011287] access to event 
reporting via the online system  from the signing of the informed consent form (ICF)  until the 
Final Visit (Day 90 or Day [ZIP_CODE]). 
Events of special interest (ESIs) and SAEs  will be  extracted by [CONTACT_436357]’s medical record  if the participant seeks medical care or if hospi[INVESTIGATOR_221255] , 
each of which notifies the site  to conduct follow up.  
Medical occurrences that begin before the start of study drug/placebo, but after obtaining 
informed consent , will not be considered an AE.  
Non-serious AEs  (or ADEs, as applicable)  may be reported by [CONTACT_2299], but will not be 
further assessed by [CONTACT_654258].  
Events of Special Interes t (ESIs) , SAEs , and U ADEs (as applicable)  will be collected from the 
start of study drug/device combination until the Final Visit (Day 90 or Day [ZIP_CODE]) or until [ADDRESS_1011288] dose/use of device if participant terminates the study  early . 
9.1.3. Assessing Causality of a Serious Adverse Event  
If an SAE occurs, the site investigator or medical monitor  will assess the relationship to study 
drug by [CONTACT_88550]:  
• Related:  
o Study drug – there is a temporal relationship between study drug and event onset 
or the event abates when study  drug is discontinued or  known to occur with study 
drug. 
o Device – an event is due to the use of the device and cannot be reasonably 
explained by [CONTACT_88551].  
• Not related: The event has no temporal relationship to study drug (or study device, as 
applicable)  or the AE  (or ADE, as applicable)  has a much more likely alternate etiology 
or is due to an underlying or concurrent illness or effect of another drug (or device, as 
applicable) . 
9.1.4. Reporting and Monitoring of SAEs  
All of the  study drugs used in this platform  protocol are repurposed medications that are 
approved for marketing in the US  for another medical condition. However, their investigational 
use for treatment  of COVID- [ADDRESS_1011289] and Fluvoxamine Maleate 100; Day 90 was the final follow -up 
day for Ivermectin 400, Fluvoxamine Maleate, and Fluticasone Furoate  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011290] to IND regulations in 21 CFR 312. The IND sponsor or designee will review SAEs 
weekly, and will perform aggregate reviews of SAEs every two weeks. The IND sponsor or her 
designee will be responsible for determining if the safety r eporting criteria are met per 21 CFR 
312.32(c)(1)(i)( C) and 21 CFR 312.32(c)(1)(iv) and will notify the Data Coordinating Center 
(DCC)  to prepare an aggregate report for submission to the FDA. An aggregate safety report will 
be submitted to FDA as soon as possible, but in no case later than [ADDRESS_1011291] from the Agency following the submission of any 
aggregate reports.  
Any UADE(s) that the IND sponsor determines is/are reportable will be submitted to the FDA, 
manufacturer, all reviewing IRBs, and all participating investigators within [ADDRESS_1011292].  
All hospi[INVESTIGATOR_88491] (see Section 10.9 ), any event that is 
determined to be COVID -19-related will not be reportable as an expedited SAE , with the 
exception of events that are related to study drug and unexpected, which will be reportable 
regardless of relatedness to COVID -19. All events that are not  COVID- 19-related per the 
adjudication process will be reviewed by [CONTACT_436358] a reportable SAE.  
Individua l SAEs and UADEs must be entered into the data system within 24 hours of site 
awareness. The DCRI Safety Surveillance  team  will notify pharmaceutical partners of SAEs 
within 1 business day of their receipt that occur involving the specific appendix of the supplied 
study drug/placebo, as required. Serious Adverse Events that are related and confirmed unlisted by [CONTACT_88553] ; as 7- day reports 
for unexpected fatal or life -threatening adverse reactions and 15- day reports for serious and 
unexpected adverse reactions. If the IND sponsor, IDMC, or FDA note a clinically important 
increase in the rate of a S[LOCATION_003]R, the IND sponsor or her designee will notify investigators no 
later than 15 calendar days a fter determining that the information qualifies for reporting.  The 
investigator will follow all reportable events until resolution, stabilization or the event is 
otherwise explained. The DCRI Safety Surveillance Team will follow all SAEs until resolution, 
stabilization, until otherwise explained.  
Pregnancies that occur while on -study will be collected and will not be followed to outcome  if 
outcome occurs beyond the participant’s Final Study Visit , however, any associated ESI or SAE 
should be reported if inf ormation can be collected and entered into the EDC. The DCRI Safety 
Surveillance team will notify pharmaceutical partners of a pregnancy within 1 business day of 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 43 receipt that occur involving the specific appendix of the supplied study drug/placebo, as 
required.  
9.1.5. Events of Special Interest  
The following are also considered E SIs to the study and will be collected by [CONTACT_88554][INVESTIGATOR_88492] :  
• Hypoxia, defined as two consecutive pulse oximetry readings ≤ 93%  
Each study drug may have a unique list of possible related ESIs. Refer to the relevant 
appendices.  
9.2. Unanticipated Problem (UP) and Terminations  
9.2.1. Definition of Unanticipated Problem  
The OHRP considers UPs  involving risks to part icipants or others to include, in general, any 
incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related doc uments, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the participant population being studied.  
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]). 
• Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
9.2.2. Reporting of an Unanticipated Problem   
The site investigator will report UPs for their participants to the DCC. The site may also be 
required to inform their reviewing IRB about a UP occurring at the local institution. The UP 
report to the DCC will include the following:  
• A detailed description of the event, incident, experience, or outcome  
• An explanation of the basis for determining that the event, incident, experience, or 
outcome represents an UP  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP  
• The DCC will document and review all UPs.  Details of the UP reporting process will be 
located in the MOP.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011293] reduced  
disease progression to hospi[INVESTIGATOR_436319]/or more rapid resolution of symptoms  as 
compared  to those who receive placebo. 
10.2. Sample Size Determination  
This study is designed to be analyzed using a Bayesian approach, accepting the possibility of 
adding and droppi[INVESTIGATOR_88493]. There is also the potential for extending 
accrual in  a study drug appendix if there is the potential to demonstrate benefit. Detailed 
simulations will be used to demonstrate the operating characteristics common to each study 
drug appendix. Decision thresholds will be set to balance overall power with contro l of the 
Type I error rate  in the context of the appendix- specific goal .  
To aid planning for this trial, symptom count  and clinical event data were estimated from 
participants in a clinical trial with similar inclusion criteria. Data were not collected daily in that 
study, but evaluations were completed on Day 10 after randomization, which is considered a 
clinically meanin gful point in time. Based on the observed distribution, it is estimated that 
studies of about n= 600 (300 study drug and 300 placebo)  will be sufficiently sized to determine 
whether there is evidence of meaningful benefit with >  85% power ( Table 2). Moreover, when 
a study drug  demonstrates overall effectiveness, the planned adaptations to increase targeted 
accrual for the purpose of demonstrating benefit on clinical events is a reasonable extension 
within the context of this platform. The final  decision thresholds and operating characteristics 
selected for  each appendix , if deviating from the common approach described in the SAP, will 
be customized  in an appendix- specific SAP . It is expected that this study will enroll up to 
15,000 adults, depending on the number of study drug appendice s that are added and 
adjustments to sample size depending on the data. [16]  
Table 2: ACTIV- 6 Sample Size Estimates and Power  
OR Corresponding 
difference in mean 
symptom burden  Power  Corresponding Risk Difference in clinical 
events  Power  
80%  85%  90%  80%  85%  90%  
0.4 2.10 75 86 101 0.025  343 392 459 
0.5 1.98 132 150 176 0.021  455 520 608 
0.6 1.86 242 277 324 0.017  675 772 903 
0.7 1.74 496 567 664 0.012  1004  1148  1343  
0.8 1.61 1267  1449  1696  0.009  1652  1889  2211  
The sample sizes given are the sample size for the study drug  arm only. Placebos will be borrowed across study drug 
appendices . The total size of the placebo arm will be equal to the size of the study drug  arm. The total number of 
placebos in the trial wil l depend on eligibility of participants among the study drug appendices  and the number of study 
drugs . The calculations are based on symptom burden, hospi[INVESTIGATOR_059], and death at Day 10.  
10.3. Randomization  
See Section 5.3.3 for additional details.   
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 45 10.4. Blinding  
The investigators , treating clinicians, and study participants will all remain blinded to study drug 
versus placebo  assignment until after the database is locked and blinded analysis is completed. 
Only the Investigational Drug Service  (IDS) and staff who are handling randomization codes and 
unblinded  member s of the biostatistical team who are preparing closed IDMC  interim reports 
will be unblinded. The statistical staff responsible for preparing IDMC reports will not directly 
interact with the clinical team that delivers care to the study participants. Specifically, study medication will be dispensed with packaging and labelling that would blind treatment 
assignment. Unblinding will occur only if required for participant safety or treatment at the 
request of the treating clinician.  
The web -based randomization system  will include blind-breaking instructions. Partici pant safety 
must always be the first consideration in making an unblinding determination. If the investigator decides that unblinding is warranted, the investigator should complete an unblinding request, which will immediately notify the Medical Monitor (s ee MOP for details) .  
10.5. Populations for Analyses 
Modified Intention to Treat (m ITT) Population:  
● All participants  who receive study drug/placebo. 
● Participants who do not receive study drug, for any reason, will be excluded; while this 
modifies the intention to treat principle,  the failure of delivery of medications from site to 
participant is not under the control of either investigator nor participants and is expected 
to occur infrequently and randomly. Similarly,  early death of a participant or withdraw al 
prior to the study drug being received is possible, but unlikely and expected to occur randomly between study drug appendices. All other participants will be included, and they will be analyzed according to which arm they were assigned. Thus, the m ITT 
analysis set includes all participants  who were randomized and received the study drug. 
Safety Population: 
● The s afety population will include those persons in the  mITT popula tion who report 
taking at least one dose of study drug or matching placebo. In the unlikely case a 
participant receives the incorrect study drug, participants will be grouped according to the treatments that they received.  
10.6. Statistical Analyses  
The main trial SAP will be finalized prior to the primary analysis.  It will include a description of 
the statistical analyses and  detailed simulations used to inform the sample size estimates. 
Appendix- specific decisions, such as choice of covariates for the model, and context specific 
decisions such as deviations in decision making threshol ds or in targeted accrual, will be made 
blinded to data and prior to analyses. Such decisions will be documented in the trial master file.  
This section is a brief summary of the planned approach to statistical analyses of the most 
important endpoints including primary and secondary endpoints. 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 46 10.6.1. General C onsiderations 
Baseline demographic and clinical variables will be summarized for each randomized arm of the 
study. Descriptive summaries of the distribution of continuous variables will be presented in 
terms of percentiles (e.g., median, 25th and 75th percentiles) along with means and standard deviations. Categorical variables will be summarized in terms of frequencies and percentages. 
Histograms and boxplots may be used to visualize the data.  
If an efficacy signal is observed at n=300 or n=600 following s IA, the trial will enter  assessment 
of the primary objective . At th at time, the pre -determined primary clinical endpoint for the 
appendix will be evaluated as either clinical events (hospi[INVESTIGATOR_30059]) or time to recovery. 
The unselected endpoint will be reported as part of the secondary objective . Both clinical 
endpoints will be analyzed using a covariate -adjusted statistical model.  
10.6.2. Statistical modeling  
Estimation and inferences about the effect of each study drug versus matching placebo will be made using Bayesian regression methods. For each study drug, the matching placebo arm will consist of concurrently randomized participants that meet the inclusion and exclusion criteria for 
that study drug. T he statistical models are described in detail in the SAP . Briefly, a longitudinal 
ordinal regression model will be used for the s IA, a logistic regression model will be used for 
clinical events, and proportional hazards models will be used for time to event analyses.  All 
models will be adjusted for covariates, including baseline symptom severity  and time from 
symptom onset . Covariates will be formally specified prior to an  analysis , taking into account 
emerging data  and changing context.  
10.6.3. Assessing Effectiveness (Primary Objective)  
The overall effect of each study drug versus matching placebo will be quantified using one of the following two primary endpoints, which will be defined and documented per study drug 
appendix prior to the initial IA : clinical events (hospi[INVESTIGATOR_30059]) or time to recovery . 
The primary analysis will be implemented separately for each study  drug appendix where the 
matching placebo arm will consist of concurrently randomized participants that meet the 
inclusion and exclusion criteria for that study drug. Decision thresholds, priors, and meaningful effect sizes may change during the course of the pandemic, as vaccination rates, case rates, and 
new therapi[INVESTIGATOR_436320]. T hresholds, effect sizes and priors, that vary during the trial 
from those described in the main SAP  will be documented in the trial master file or other 
designated document . Prior to any interim or final analysis, all decision thresholds, priors and 
effect sizes will be confirmed and evaluated using ext ensive simulations to demonstrate the 
overall Type I error rate remains below 0.05. A n mITT approach  will be used  for primary 
analyses. All available data will be used to compare each  study drug versus placebo control, 
regardless of post -randomization adhe rence to study protocols.  
10.6.4. Interim Analyses (IA) , Early Stoppi[INVESTIGATOR_007], and Type -I Error Control  
Individual study drugs may require different sample sizes, and the sample sizes may be adjusted 
based on the results of IA . Therefore, fixed enrol lment triggers will be used for IA . An IA  will 
occur after enrol lment and completion of 14 day follow -up of approximately every 300 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 47 participants in a study arm  (150 in study drug arm and 150 in placebo arm) . Study drug 
appendi ces may be stopped early for ef ficacy or futility  (see Figure 2) . Thresholds are described  
in the SAP  to guide stoppi[INVESTIGATOR_740092] .  
The following schedule and decision thresholds will be followed  for IA s: 
i) Screening IA (n=300):  
a. The study drug is found to have benefit (efficacy). Study drug appendix will 
proceed to primary objective IA a t n=300. Note: this is also a check for harm as 
all assessments are two -tailed.  
b. The study drug is not found to have benefit, enrollment continues in the study drug appendix and sIA is repeated at n=600. 
ii) Screening IA (n=600):  
a. It would be futile to attempt to show a benefit of the study drug based on the 
predicted probability of success  (PPOS)  and other factors . The study drug 
appendix will be terminated.  
b. Futility is not determined . Study drug appendix will proceed to primary objective 
IA at n=600.  
iii) Primary Objective IA (n=300): if the criteria for proceeding to the primary objective 
are met when n=300, a primary objective IA will be conducted. The following 
decisions will be assessed:  
a. The study drug is found to have benefit (efficacy) , the study drug appendix will 
be terminated as the primary endpoint has been met.  
b. It would be futile to attempt to show a benefit of the study drug within the PPOS 
and other factors . The study drug appendix will be terminated.  
c. Efficacy/futility is undeterminable,  enrollment will continue in the study drug 
appendix and the primary objective IA will be assessed at n= 600.  
iv) Primary Objective IA (n=600 , 900): if the criteria for proceeding to the primary 
objective IA are met when n=600 or n=900, a primary objective IA w ill be 
conducted. The following decisions will be assessed:  
a. The study drug is found to have benefit (efficacy) , the study drug appendix will 
be terminated as the primary endpoint has been met.  
b. It would be futile to attempt to show a benefit of the study dr ug based on the 
PPOS and other factors . The study drug appendix will be terminated.  
c. Efficacy/futility is undeterminable,  enrollment will continue in the study drug 
appendix and the primary objective will be assessed after another [ADDRESS_1011294] bee n enrolled, or until n=1200.  
The analysis for the sIA will use a covariate adjusted statistical model. The outcome is an ordinal 
variable, which is the overall symptom burden measured on a none  / mild  / moderate  / severe 
scale with hospi[INVESTIGATOR_478623] 5
th and 6th level of the ordinal scale. The 
outcome is measured daily for 14 days. The outcome is compared between participants receiving 
study drug and participants receiving placebo each of the 14 days using a longitudinal statistical 
model that takes into account the repeated measurements on each participant. The statistical 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 48 model can be used to estimate the days of benefit – the number of days for which being on an 
active study drug results in a better outcome than being on a comparator. Days benefit, restated 
in terms of concordance and discordance probabilities, is the difference between (a) the 
probability that the intervention is better and (b) the probability that the non- intervention is 
better, summed over all the days of follow -up. This is the main quantity, or estimand, that will be 
used to make early go/no- go decisions for each appendix.  
The primary objective IA will follow processes described in Section 10.6.3 for assessment of 
efficacy. The primary endpoint  used for the primary objective IA  will be selected  per appendix 
prior to the  initial  IA.  
A posterior probability of meaningful benefit for a s tudy drug in comparison to the placebo 
control of greater than the s pecified threshold will result in a declaration of overall superiority. A 
PPOS when n=[ADDRESS_1011295] 5% , as described in the SAP . 
10.6.5. Sensitivity and Supplementary Analyses  
The sensitivity analyses described in the SAP are designed to test robustness of the results to 
assumptions in the statistical models.  In addition to checking assumptions about the modeling 
approach, association of adherence with outcomes  will also be ascertained . In the main statistical 
mode l, the number of doses of  study drug consumed will be added as a covariate.  
10.6.6. Differential T reatment Effects and Subgroup A nalyses  
Differential treatment effect, also referred to as heterogeneity of treatment effect, refers to differences in treatment efficacy as a function of pre- existing pa rticipant characteristics such as 
baseline variables. This is often assessed by [CONTACT_478669]. However, these subgroups do 
not inherit the baseline covariate adjustment of the full pa rticipant outcome model, and are 
problematic because of imp roper subgroupi[INVESTIGATOR_143395] a continuous variable is used. For example, 
dichotomizing age at [ADDRESS_1011296] will be prespecifi ed and model based.  
For example, effectiveness vari ability can be estimated with continuous age by [CONTACT_1583] a smooth 
age by [CONTACT_740104] -6 Protocol [v6.0] 
 
 [ADDRESS_1011297] and their uncertainties across age = 10, 11, …, 100. Differential 
treatment effects by [CONTACT_4321], body mass index, and age will be examined . Prior to the final analysis, 
additional important subgroupi[INVESTIGATOR_436323]. K nowledge 
about concomitant therapi[INVESTIGATOR_014], risk factors, and vaccinations are expected to continue to evolve 
and inform the final decision on their inclusion in these analyses.  
Studies under this master protocol will be sized only for ass essing overall study drug effects. 
Thus, there may be inadequate power to (1) examine interactions and to (2) estimate covariate -
specific treatment effects (e.g., odds ratio at age 70 or for females) . 
10.6.7. Secondary Clinical Endpoint  
The COVID Clinical Progression  Scale score on Day 1 4 will be compared between participants  
in each study drug arm  and the placebo arm  using a covariate adjusted proportional odds model . 
A similar approach will be used for QOL outcomes. Covariates will be prespecified and will 
include at a minimum: age, baseline severity, and duration of illness . The proportional odds 
assumption will mainly be examined using graphical methods —e.g., the logit of the empi[INVESTIGATOR_740093]. If proportionality is clearly violated, a partial proportional odds or non- proportional 
odds models  will be considered . As before, a Bayesian approach to model interpretation will b e 
used. For estimating time to symptom resolution  based on the definition of at least three 
consecutive days without symptoms, a proportional hazards model will be used. Since death is a 
competing risk, cause- specif ic hazards will be estimated . Observations will be censored at [ADDRESS_1011298] of treatment on long term outcomes, 
the SAP will describe how participant state during the intervention period will be used t o inform 
longer term outcomes.  
10.6.9. Adherence and Retention Analysis  
Withdrawals from study drug and consent withdrawals will be tracked via the online system .  
Participants will be asked about  their use of study drug. Those reporting discontinuation or 
switch ing will be asked about the reasons for discontinuation/switching.   
Measures of study retention to inform follow -up time will be based on several measures, 
including web -based check -ins for symptoms and COVID- [ADDRESS_1011299] and Fluvoxamine Maleate 100; Day 90 was the final follow- up 
day for Ivermectin 400, Fluvoxamine Maleate, and Fluticasone Furoate  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 50 10.7. Interim Reporting   
In addition to routine evaluation of decision thresholds pursuant to the statistical design of this 
study, r egular IDMC reviews will be conducted to ensure the safety of study participants.  
Regular IDMC  meetings will monitor the following parameters at a minimum:  
• Recruitment progress  
• Enrollment overall and by [CONTACT_12125]  
• Adherence, retention, and status of data collection  
• Events of special interest  (ESIs)  
• Unanticipated problems  
• Serious adverse events (SAEs ) 
Interim examination of clinical endpoints will be based on the accrual of primary endpoint data.  
It is expected that reviews of the data will occur approximately after each 300 participants  are 
enrolled in each study drug appendix (1 50 in study drug arm  and 150 in placebo arm) .  
For ethical reasons, interim examinations of key safety and process data will be performed at 
regular intervals during the course of the trial. The  DCC will create reports to track pa rticipan t 
enrollment, rates of adherence with the assigned treatment strategy, and frequency of protocol 
violations. Prior to each meeting, the DCC will conduct any requested statistical analyses and 
prepare a summary report along with the following information: pa rticipa nt enrollment reports, 
rates o f adherence with the assigned treatment, and description of SAEs.  
Safety reports will be prepared for the IDMC approximately weekly once enrollment begins. The 
prespecified stoppi[INVESTIGATOR_88504] a strict rule for early termination.  It is expected that both internal and external factors will 
influence the decisions of the IDMC. The SAP  will describe the planned interim analyses and 
futility monitoring in detail . 
10.8. Independent Data Monitor ing Committee  (IDMC ) 
The IDMC will monitor participant safety and study performance. A n IDMC charter that outlines 
the operating guidelines for the committee and the procedures for the interim evaluations of study data will be developed and agreed upon by [CONTACT_31849]. Reports will be prepared by [CONTACT_88558], or as requested by [CONTACT_88559], and 
will include interim analyses of primary and secondary endpoints, additional safety events, and 
other information as r equested by [CONTACT_942]. After each scheduled closed meeting, the 
IDMC will send a recommendation to the IND sponsor  to continue, modify, or terminate  the 
study. After approval, the recommendations will be forwarded by [CONTACT_436360] (CCC)  to investigators for submission to their local, regional and national IRB /Ethic 
Committees, as applicable. Please refer to the IDMC  Charter  for further details . 
10.9. Adjudication Committee  
The medical records will be requested for all participants reporting a hospi[INVESTIGATOR_139074]/or de ath 
at any point during the study. For each participant -reported hospi[INVESTIGATOR_740094], t he 
DCRI Clinical Ev ent Ascertainment (CEA) group will review the medical records and confirm 
the occurrence and root cause of the event as part of an adjudication process. The CEA group 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011300], a dditional details 
about review procedures will be provided in an adjudication charte r.  
 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011301] (IRB) 
The protocol, ICF(s), recruitment materials, and all participant materials will be submitted to the  
IRB(s)  of record for review and approval . This approval must be obtained before any participant 
is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_1201](s) 
before being implemented in the study. All changes to the consent form will also be IRB -
approved and a determination will be made regarding whether previously consented p articipants 
need to be re -consented.  
11.2. Informed Consent Process  
All consenting will occur either via an electronic consent process or a paper process. Consent 
forms describing in detail the study drug/placebo,  study procedures, and risks will be  given to the  
participant and documentation of informed consent is required prior to starting study procedures. 
Informed consent is a process that is initiated prior to the individual’s agr eement  to participate in 
the study and continues throughout the individual’s study participation. A description  of risks 
and possible benefits of participation will be provided to the participants.  A description of the 
current available therapi[INVESTIGATOR_740095] . Consent forms will be IRB -approved and the participant will be asked to read and 
review the document. The participant will be provided a phone number and email in the event they have questions about study participation. This will allow them to communicate with the 
investigator s (or their delegate), for further  explana tion of the research study and to answer any 
questions that may arise, as necessary . Participants will have the opportunity to carefully review 
the consent form and ask questions prior to signing. 
The participants should have the opportunity to discuss the study and think about it prior to 
agreeing to particip ate. The participant will sign the informed consent document prior to any 
procedures being done specifically for the study. The participants may withdraw consent at any 
time throughout the course of the study. A copy of the informed consent document will be 
provided to the participants for their records. The rights and welfare of the participants will be 
protected by [CONTACT_40749].  
The st udy team will distinguish between the desire to discontinue study drug and the desire to 
withdraw consent for study follow -up. In the event that a participant withdraws consent, the 
investigator or his /her designee will clarify with the participant and doc ument whether the 
withdrawal is temporary or permanent, and if a full or partial withdrawal.  
11.3. Participant and Data Confidentiality  
Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, 
and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological 
samples in addition to the clinical and private information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will  be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011302] party without prior written approval of the sponsor. The study participant’s contact 
[CONTACT_740105].  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at the DCC. The study data entry and study 
management systems used by [CONTACT_740106]. At the end of the study, all study- related data storage systems will be archived  
according to local processes.  
11.4. Site Management and Quality Assurance 
The study team will work in tandem to ensure that the data collected in this study are as complete 
and correct as possible. A four -step, multi -functional approach to quality control  will be 
implemented : 
• Training: Prior to the start of enrollment, the clini cian investigators and key study 
personnel  at each site will be trained with the clinical protocol and data collection 
procedures, including how to use the Electronic Data Capture (EDC) system. F ollow -up 
training and training for new study personnel or new  versions of the protocol will be 
conducted as needed.  
• Monitoring: The CCC, along with the DCC, will ensure that data collection is handled 
properly, will provide in -service training, and will address questions from site investigators 
and coordinators. Ele ctronic r eview  of data quality and completeness will occur  on a  
regular and ongoing basis. Any issues will be addressed . At a minimum, s ource document 
verification will occur, as needed, for confirmation of COVID -19 diagnosis and 
hospi[INVESTIGATOR_059](s).  
• Managing data: After the data have been transferred for statistical summarization, data description, and data analysis, further crosschecking of the data will be performed with discrepant observations being flagged and appropriately resolved through a data  query 
system.  
• Reviewing data: Data regarding e vents of interest will be reviewed to ensure appropriate 
documents are collected for IDMC review. The DCC will monitor standardized classification of symptoms  and contact [CONTACT_740107] g the 
primary endpoint  are not complete . 
11.5. Site Monitoring  
This study will employ a centralized risk -based approach to monitoring with routine and periodic 
review of participant- submitted data to validate the informed consent process, select eligibility 
criteria, hospi[INVESTIGATOR_059], identify and follow -up on missing data, inconsistent data, data outliers, 
etc. and ensure completion of administrative and regulatory processes. The study team will 
facilitate regular communication through training se ssions, teleconferences, videoconferencing, 
email, etc. Using quality -by-design principles , steps  will be  taken at the study design stage to 
foresee and limit problems that might occur during the study conduct. Follow -up from the online 
system  and call cen ter is expected to keep participants engaged. Minimal levels of intervention 
and a focus on observing rather than influencing the study participants greatly increases the 
likelihood that Good Clinical Practices will be followed. Central statistical monitoring is 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 54 particularly useful for identifying unusual patterns in data. An  integrated approach to quality 
surveillance will be deployed, which will be detailed in the appropriate study management plans. 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011303] (HIPAA)  compliant.  
Site personnel or participants will enter study data into a se cure online database. D ata will be 
maintained  in a secure online database until the time of study publication. At the time of 
publication, the DCC will generate a de- identified version of the database  for archiving (see 
Section 12.4 ). 
12.2. Study Records Retention  
Study documents should be  retained for a minimum of six  years after the study has ended. 
However, if required by [CONTACT_427], these documents should be ret ained for a longer 
period. No records will be destroyed without the written consent of the sponsor, if applicable. It 
is the responsibility of the sponsor to inform the investigator when these documents no longer 
need to be retained.  
12.3. Protocol Deviations  
A protocol deviation is defined as non-compliance with the  clinical study protocol, GCP, or 
MOP requirements. The  non-compliance may be on the part of the partici pant, site inv estigator, 
or the si te staff.  
A major  protocol deviation is a significant divergence from the protocol that may have 
significant effect on the participant’ s safety, rights, or welfare and/or on th e integrity of the study 
data. Major protocol deviations  must be sent to the study IRB and l ocal IRB per t heir guidelines, 
recorded in s ource documents, and r eported to the coordinating center. Major protocol deviations 
will be tracked . For this study, any missed or delayed survey completion will not be considered a 
major protocol deviation. Refer to the MOP for details.  
12.4. Publication and Data Sharing Policy  
This study will comply with the NIH Public  Access Policy, which  ensures that the public  has 
access to the results of NIH- funded rese arch. Methods of data sharing will include 1) archiving 
de-identified data in a data repository and 2) sharing of limited datasets under a Data Use 
Agreement (DUA) and IRB approval. Data will be made available to qualified investigators by 
[CONTACT_88563] a fully de -identified dataset in  a platform to be determined at the end of the trial . Both 
repositories allow users to search, view study information, and then submit an application to 
receive data. Prior to archiving study dat a, the DCC will produce a final dataset that will be 
stripped of all personal health information (PHI) in compliance with the HIPAA privacy rule. 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011304] peer -reviewe d 
journals. The International Committee of Medical Journal Editors (IC MJE) member journals have  
adop ted a cli nical studies  registration policy as a condition for publicat ion. The ICMJE defines a 
clinical study as  any research p roject that prospe ctively assigns human participants  to 
intervention or concurrent c omparison or control groups t o study the cause-and-effect 
relationship between a medical intervention and a health outcome. The ICMJE  policy, and  the 
Section [ADDRESS_1011305] of 2007, requ ires t hat all 
clinical studies be regi stered in  a public registry such  as ClinicalTrials .gov, which is spons ored 
by [CONTACT_88564]. For interventional cli nical trials per formed under  NIH IC 
grants and cooperative agreements, it is the gra ntee’s responsibility to register the study in an 
acceptable registry, so the rese arch results may be considered f or publicati on in ICMJE  member 
journals.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 57 13. Study Leadership  
The Steering Committee is a multi- stakeholder committee that oversees the study and includes 
representatives from clinical sites, the trial coordinating center, the NIH, PCORI, Operation 
Warp Speed, the FDA , National Center for Advancing Translational Scie nces (NCATS), ACTIV 
representatives with no conflict of interest, and academic and industry advocates .  
The CCC and DCC are each overseen by [CONTACT_976] (s). The CCC is responsible for study coordination, 
site management, communication, and financial administrat ion. The DCC is responsible for 
treatment allocations, receipt and processing of data, quality control programs, and statistical 
analysis and reporting.   
An independent IDMC will oversee the safety and welfare of trial participants as well as provide 
recommendations for continuation, discontinuation or revision of the trial. 
 
 
Figure 3: Operational Structure Diagram  

CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 58 14. Summary of Changes  
Protocol Version (version #, date)  Summary of Changes  
Version 1.0, 01APR 2021 N/A, Version 1.0 
Version 2.0, 25MAY2021 • Added current use of study drug or 
study drug/device combination as an exclusion criteria (Sections 1.1 and 
5.2); 
• Added a  phone call follow -up the day 
after first study drug dose , clarified that 
follow -up w ill occur if two consecutive 
days of reporting are missed during Days 3 -14, and added that sites/call 
center will collect missing survey information during follow -up calls 
(Section 7.3 ); 
• Added at-home pulse oximetry readings 
and description of at -home pulse 
oximetry reading collection ( Table 1 
and Section 8.2); 
• Added symptom severity scale (Section 8.2); 
• Added Adverse Device Effect and 
Unanticipated Adverse Device Effects definitions, collection/reporting period details, and causality assessment details (Sections 9.1.1, 9.1.2, 9.1.3, 9.1.4);  
• Clarified that hypoxia ESI will only be collected from hospi[INVESTIGATOR_88492] (Section 9.1.5);  
• Clarified that any missing or delayed 
survey completion will not be 
considered a major protocol deviation (Section 12.3);  
• Updated Ivermectin and matched 
placebo information and packaging (Sections 16.3, 16.3.1, 16.3.3, 16.4.1);  
• Added Appendix B – Fluvoxamine 
maleate (Section 17 ); 
• Added Appendix C – F luticasone 
Furoate (Sectio n 18); 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 59 • Changed symptom freedom to 
symptom resolution for consistency 
throughout;  
• Other administrative changes throughout.  
Version 3.0, 06JUL 2021 • Clarified that the sample size increase will included 1:1 active study drug to placebo (Section 1.1); 
• Added footnote 6 to COVID -19 
Outcomes during Intervention Period  to 
clarify that these will be assessed on Day 7 and 14 ( Table 1) ; 
• Added that events that are COVID -19 
related AND study drug related and unexpected will  be considered 
reportable (Section 9.1.4) ; 
• Updates made to fluvoxamine appendix: excluded linezolid, use of fluoxetine within 45 days of consent, and bipolar disorder  per FDA feedback 
(Section 17.2); added precautions of additional drugs including t ramadol, 
buspi[INVESTIGATOR_5331], fentanyl, lithium, amphetamines, St. John’s Wart, 
carbamazepi[INVESTIGATOR_050], quinidine, and tacrine  
per FDA feedback (Section 17.2.1) ; 
• Updates made to fluticasone furoate appendix: brand name [CONTACT_436378] (Section 18); changed liver 
failure exclusion criteria to “m oderate 
to severe hepatic impairment, defined as Child -Pugh B or C ” (Section 18.2 ); 
removed hepatic impairment precautions as it was added to exclusion criteria (Section 18.2.1) ; 
• Other minor administrative changes throughout . 
Version 4.0, 20DEC2021 • Removed protocol number as no 
protocol number will be assigned;  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 60 • Changed primary objective from 
symptom reduction to effectiveness 
based on clinical outcome endpoints of hospi[INVESTIGATOR_059]/death or time to recovery (Sections 
1.1 and 3);  
• Removed unnecess ary “ e.g., 
hospi[INVESTIGATOR_9017]” from first secondary objective ( Sections 1.1 and 
3);  
• Added rationale  for sIA (Sections 1.1 
and 4);  
• Inclusion criterion #3:  added 
reinfection (Sections 1.1  and 5.1);  
• Exclusion criteria updates: Removed “prior diagnosis of COVID -19 infection 
(>10 days from sc reening)” as it was 
causing confusion for sites and is already covered by [CONTACT_436363] #3; specified that current or recent hospi[INVESTIGATOR_53763] -19 infection 
is exclusionary, not all hospi[INVESTIGATOR_602]; added a time window for current or recent u se of study drug or combination 
for within the last 14 days; added “current or planned participation in another interventional trial to treat COVID- 19, at the discretion of the 
study PI ” (Sections 1.1 and  5.2);  
• Sample size considerations updated to include sIA (Sections 1.1 and 10.2) ; 
• Statistical considerations for Primary Analysis updated to align with change in primary objective and IAs (Section s 
1.1, 10.6.1, and 10.6.3);  
• Interim Analysis updated to specify that IA will occur ~ every 300 participants instead of every 200, included sIA, and primary objective IA (Sections 1.1, 10.6.4, and 10.7);  
• Added Figure 2
 to portray IA process 
(Section 1.2); 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 61 • Updated study background and 
rationale based on new data (Sectio ns 
2.1 and 2.2) ; 
• Updated secondary outcome measures 
and reported endpoints (Section 3 );  
• Added additional informati on regarding 
arm eligibility depending on the number of arms open to provide clarity for sites (Section 4.1); 
• Added that screen failures also include participants who  consent, then on 
review by [CONTACT_779], are found to be ineligible for the study (Section 5.4 ); 
• Added additional reasons why participant may not receive study drug/placebo and specified that these participants would be identified as randomized not enrolled, instead of consented not enrolled (Section 5.5 ); 
• Specified that participants will be contact[CONTACT_436364] 3 to 14 (Section s 7.3 and 9.1.2) ; 
• Clarified that all participants will be asked to complete symptom reporting 
on Days 21 and 28, regardless of symptom resolution ( Table 1, Section 
8.1.3) ; 
• Added that “overall symptom burden” is collected as part of Symptom Reporting (Secti on 8.2 ); 
• Updated primary hypothesis to align with updated primary objective (Section 10.1.1) ; 
• Model priors section removed and Statistical modeling simplified to refer to detailed description in SAP as models will be adjusted per appendix (Section 10.6.2) ; 
• Removed details of sensitivity analysis 
and referred to SAP (Section 10.6.5 ); 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 62 • Clarified that additional subgroupi[INVESTIGATOR_740096] (Section 10.6.6 ); 
• Changed Appendix A – Ivermectin title to Ivermectin 400 (Section 16); removed CYP3A4 and P -gp 
precautions as not noted in the IB for the ivermectin stud y drug (Section 
16.2.1); in Section 16.2, deleted “use of warfarin, CYP3A4, P -gp inhibitor 
drugs, or CYP3A4 substrates” appendix- level exclusion criteria and 
added “Current or planned use of the 
following drugs:  
o Antiarrhythmic/antihy pertensive 
drug class: quinidine, 
amiodarone, diltiazem, spi[INVESTIGATOR_8407], verapamil  
o Antibiotic -macrolides drug 
class: clarithromycin, erythromycin 
o Antifungal drug class: itraconazole, ketoconazole  
o Immunosuppresant drug class: cyclosporine, tacrolimus  
o Anti-HIV drug class: indinavir, 
ritonavir” ; 
• Added Appendix D – Ivermectin 600 (Section 19) ; 
• Other administrative changes  
throughout.  
Version 5.0, 17MAR2022  • Added illness severity objective (Sections 1.1  and 3);  
• Removed reference to appendix-specific SAP, only significant deviations from the main SAP analysis will require appendix- specific SAPs. 
Choice of primary objective, covariates, etc. will be documented outside of the SAP (Sections 1.1, 10.2, 10.6, 10.6.3, 
10.6.4 ); 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 63 • Clarified that primary objective occurs 
at 28 days (Sections 1.1 and 3);  
• Updated COVID- 19 status, vaccination, 
and treatment options background 
(Sections 1.1  and 2.1);  
• Defined “receipt of study drug” (Section 5.5 ); 
• COVID- 19 vaccination added to 
abbreviated medical history (Section 8.2); 
• Updated instructions for unblinding (Section 10.4);  
• Specified that covariates will take into account emerging data and changing context (Section 10.6.2); 
• Added that this study operates in addition to usual care  in additional 
protocol locations (Sections 11.2 and 
2.1); 
• Appendix A close d to enrollment on 
04FEB2022;  
• Appendix C closed to enrollment on 08FEB2022;  
• Added Appendix E – Combination Fluvoxamine Maleate and Fluticasone Furoate;  
• Added Appendix F – Montelukast (Section 21);  
• Other administrative changes throughout.  
Version 6.0, 17JUN2022  • Appendix B closed to enrollment on 27FEB2022;  
•  Removed appendix for combination fluvoxamine maleate and fluticasone furoate arm;  
• Added Appendix E – Fluvoxamine Maleate 100;  
• Added neuropsychiatric events of special interest in Montelukast appendix;  
• Updated the final visit from 90 to 120 
days, effective only for arms 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011306]  (footnotes added 
throughout  for Day 120) ; 
• Other administrative changes 
throughout.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 65 15. References  
1. COVID-19 Map FAQ . 2020  [cited 2020; Available from: 
https://coronavirus.jhu.edu/map-faq.html . 
2. McIntosh, K. Coronavirus disease 2019. 2020  [cited 2020 March 24]. 
3. Beigel, J.H., et al., Remdesivir for the Treatment of Covid -19 — Final Report. New 
England Journal of Medicine, 2020. 383(19): p. 1813-1826. 
4. Dexamethasone in Hospi[INVESTIGATOR_61013]-19 — Preliminary Report. New 
England Journal of Medicine, 2020. 
5. Gordon, A.C., et al., Interleukin -6 Receptor Antagonists in Critically Ill Patients with 
Covid -19 – Preliminary report.  medRxiv, 2021: p. 2021.01.07.21249390. 
6. Baden, L.R., et al., Efficacy and Safety of the mRNA-1273 SARS- CoV-2 Vaccine. New 
England Journal of Medicine, 2020. 384(5): p. 403-416. 
7. Polack, F.P., et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New 
England Journal of Medicine, 2020. 383(27): p. 2603-2615. 
8. Voysey, M., et al., Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) 
against SARS- CoV-2: an interim analysis of four randomised controlled trials in Brazil, 
South Africa, and the [LOCATION_006]. The Lancet, 2021. 397([ZIP_CODE]): p. 99-111. 
9. Wang, Z., et al., mRNA vaccine -elicited antibodies to SARS- CoV-2 and circulating 
variants. bioRxiv, 2021: p. 2021.01.15.426911. 
10. Grein, J., et al., Compassionate Use of Remdesivir for Patients with Severe Covid -19. 
New England Journal of Medicine, 2020. 382(24): p. 2327-2336. 
11. Beigel, J.H., et al., Remdesivir for the Treatment of Covid -19 — Preliminary Report.  New 
England Journal of Medicine, 2020. 
12. Wyatt, M.A., et al., Implementation of the “Pregnancy Reasonably Excluded Guide” for 
Pregnancy Assessment : A Quality Initiative in Outpatient Gynecologic Surgery.  
Obstetrics & Gynecology, 2018. 132(5): p. 1222-1228. 
13. Print, W.H.O.R.D.B. Novel Coronavirus COVID -19 Therapeutic Trial Synopsis . 2020. 
14. Cella, D., et al., The Patient-Reported Outcomes Measurement Information System 
(PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care, 2007. 45([ADDRESS_1011307] 1): p. S3-S11. 
15. Hays, R.D., et al., PROMIS(®) -29 v2.0 profile physical and mental health summary 
scores.  Quality of lif e research : an international journal of quality of life aspects of 
treatment, care and rehabilitation, 2018. 27(7): p. 1885-1891. 
16. Whitehead, J., Sample size calculations for ordered categorical data. Stat Med, 1993. 
12(24): p. 2257-71. 
17. Boussinesq, M., et al., Clinical pi[INVESTIGATOR_1103], epi[INVESTIGATOR_88508]- associated 
serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria journal, 2003. [ADDRESS_1011308] 1 (Suppl 1): p. S4- S4. 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 66 18. Makenga Bof, J.C., et al., Onchoce rciasis control in the Democratic Republic of Congo 
(DRC): challenges in a post -war environment. Trop Med Int Health, 2015. 20(1): p. 48-
62. 
19. Chandler, R.E., Serious Neurological Adverse Events after Ivermectin -Do They Occur 
beyond the Indication of Onc hocerciasis?  Am J Trop Med Hyg, 2018. 98(2): p. 382 -388. 
20. Barkwell, R. and S. Shields, Deaths associated with ivermectin treatment of scabies.  
Lancet, 1997. 349(9059): p. 1144- 5. 
21. MERCK & CO., I. TABLETS STROMECTOL (R) (IVERMECTIN) Product Label . 2009  
[cited 2021 February 12]; Available from: 
file:///U:/Personal/My%20Documents/Medical%20Writing/COVID/ACTIV -
6/Study%20Drugs/Ivermectin.pdf.  
22. Nicolas, P., et al., Safety of oral ivermectin during pregnancy: a systematic review and 
meta -analysis. The Lancet Global Health, 2020. 8 (1): p. e92 -e100. 
23. Pacqué, M., et al., Pregnancy outcome after inadvertent ivermectin treatment during 
community -based distribution. The Lancet, 1990. 336(8729): p. 1486- 1489. 
24. Addiss, D.G., et al., Randomised placebo- controlled comparison of ivermectin and 
albendazole alone and in combination for <em>Wuchereria bancrofti</em> microfilaraemia in Haitian children. The Lancet, 1997. 350(9076): p. 480 -484. 
25. Dreyer, G., et al., Treatment of bancroftian filariasis in Re cife, Brazil: a two -year 
comparative study of the efficacy of single treatments with ivermectin or diethylcarbamazine. Trans R Soc Trop Med Hyg, 1995. 89(1): p. 98- 102. 
26. Heukelbach, J., S. Franck, and H. Feldmeier, Therapy of tungiasis: a double -blinded 
randomized controlled trial with oral ivermectin. Mem Inst Oswaldo Cruz, 2004. 99(8): 
p. 873- 6. 
27. Martin -Prevel, Y., et al., Tolerance and efficacy of single high -dose ivermectin for the 
treatment of loiasis.  Am J Trop Med Hyg, 1993. 48(2): p. 186- 92. 
28. Smit, M.R., et al., Safety and mosquitocidal efficacy of high -dose ivermectin when co -
administered with dihydroartemisinin- pi[INVESTIGATOR_88509] (IVERMAL): a randomised, double -blind, placebo- controlled trial. Lancet In fect 
Dis, 2018. 18(6): p. 615 -626. 
29. LLC, E.P., Ivermectin Tablets USP, 7mg, 14mg Investigator's Brochure . 2021. 
30. Yang, S.N.Y., et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res , 2020. 177: p. 104760. 
31. Caly, L., et al., The FDA- approved drug ivermectin inhibits the replication of SARS- CoV-
2 in vitro. Antiviral Research, 2020. 178: p. 104787. 
32. Lehrer, S. and P.H. Rheinstein, Ivermectin Docks to the SARS -CoV-2 Spi[INVESTIGATOR_400780]-
binding Domain Attached to ACE2. In Vivo, 2020. 34(5): p. 3023- 3026. 
33. Guzzo, C.A., et al., Safety, tolerability, and pharmacokinetics of escalating high doses of 
ivermectin in healthy adult subjects.  Journal of clinical pharmacology, 2002. 42(10): p. 
1122- 1133. 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 67 34. Chaccour, C., et al., Ivermectin and COVID -19: Keepi[INVESTIGATOR_88511]. Am 
J Trop Med Hyg, 2020. 102(6): p. 1156- 1157. 
35. Arshad, U., et al., Prioritization of Anti -SARS -Cov-2 Drug Repurposing Opportunities 
Based on Plasma and Targe t Site Concentrations Derived from their Established Human 
Pharmacokinetics. Clin Pharmacol Ther, 2020. 108(4): p. 775- 790. 
36. Bray, M., et al., Ivermectin and COVID -19: A report in Antiviral Research, widespread 
interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral 
research, 2020. 178: p. 104805- 104805. 
37. Zhang, X., et al., Ivermectin inhibits LPS -induced production of inflammatory cytokines 
and improves LPS- induced survival in mice.  Inflamm Res, 2008. 57(11): p. 524- 9. 
38. Ci, X., et al., Avermectin exerts anti -inflammatory effect by [CONTACT_88565]- B and mitogen- activated protein kinase activation pathway. 
Fundam Clin Pharmacol, 2009. 23(4): p. 449- 55. 
39. DiNicolantonio, J.J., J. Barroso -Arranda, and M. McCarty, Ivermectin may be a clinically 
useful anti -inflammatory agent for late -stage COVID- 19. Open Heart, 2020. 7(2): p. 
e001350. 
40. Ahmed, S., et al., A five -day course of ivermectin for the treatment of COVID -[ADDRESS_1011309] Dis, 2021. 103: p. 214- 216. 
41. Chachar, A.Z.K., et al., Effectiveness of Ivermectin in SARS -CoV-2/COVID- 19 Patients. 
International Journal of Sciences, 2021. 
42. Abu Taiub Mohammed Mohiuddin, C., et al., A Randomized T rial of Ivermectin -
Doxycycline and Hydroxychloroquine -Azithromycin therapy on COVID19 patients. 
Research Square, 2021.  
43. Soto-Becerra, P., et al., Real-World Effectiveness of Hydroxychloroquine, Azithromycin, 
and Ivermectin Among Hospi[INVESTIGATOR_60992] -19 Patients: Results of a Target Trial 
Emulation Using Observational Data from a Nationwide Healthcare System in Peru. 
SSRN Electronic Journal, 2020. 
44. Hashim, H.A., et al., Controlled randomized clinical trial on using Ivermectin with Doxycycline for treatin g COVID- 19 patients in Baghdad, Iraq. medRxiv, 2020: p. 
2020.10.26.20219345. 
45. Khan, M.S.I., et al., Ivermectin Treatment May Improve the Prognosis of Patients With 
COVID- 19. Arch Bronconeumol, 2020. 56(12): p. 828- 830. 
46. Morgenstern, J., et al., The u se of compassionate Ivermectin in the management of 
symptomatic outpatients and hospi[INVESTIGATOR_88512] -[ADDRESS_1011310] 10, 2020. medRxiv, 2020: p. 
2020.10.29.20222505. 
47. Krolewiecki, A., et al., Antiviral Effect of High -Dose Ivermectin in Adults with COVID -
19: A Pi[INVESTIGATOR_88513], Controlled, Open Label, Multicentre Trial . 2020, SSRN.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 68 48. Podder, C.S., et al., Outcome  of ivermectin treated mild to moderate COVID -19 cases: a 
single- centre, open -label, randomised controlled study. IMC Journal of Medical Science, 
2020. 14(2).  
49. Ravikirti, et al., Ivermectin as a potential treatment for mild to moderate COVID-19 – A 
double blind randomized placebo- controlled trial.  medRxiv, 2021: p. 
2021.01.05.21249310. 
50. Morteza Shakhsi, N., et al., Research Square, 2021. 
51. Espi[INVESTIGATOR_54604] -Hernandez, G., et al., Effects of Ivermectin -azithromycin -cholecalciferol 
combined therapy on COVID-19 infected patients: A proof of concept study.  Biomedical 
Research, 2020. 
52. Babalola, O., et al., Ivermectin shows clinical benefits in mild to moderate COVID19: A 
randomised controlled double blind dose response study in Lagos. medRxiv, 2021: p. 
2021.01.05.21249131. 
53. NIH. COVID-19 Treatment Guidelines Fluvoxamine . 2021  [cited 2021 April 23]; 
Available from: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/fluvoxamine/
. 
54. Apotex, Higlights of Fluvoxamine Maleate Tablets Prescribing Information. 
55. Lenze, E.J., et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients 
With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA, 2020. 324(22): p. 
2292-2300. 
56. Rosen, D.A., et al., Modulation of the sigma -1 receptor–IRE1 pathway is beneficial in 
preclinical models of inflammation and sepsis. Science Translational Medicine, 2019. 11(478): p. eaau5266.  
57. Rafiee, L., V. Hajhashemi, and S.H. Javanmard, Fluvoxamine inhibits some inflammatory 
genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic Med Sci, 20 16. 19(9): p. 977-984. 
58. Seftel, D. and D.R. Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of 
Coronavirus Disease 19.  Open Forum Infectious Diseases, 2021. 8(2).  
59. GlaxoSmithKline, Highlights of Prescribing Information for Arnuity Ell ipta. 2018: 
Online. 
60. Yamaya, M., et al., Inhibitory effects of glycopyrronium, formoterol, and budesonide on 
coronavirus HCoV -229E replication and cytokine production by [CONTACT_88566][INVESTIGATOR_1663]. Respir Investig, 2020. 58(3): p. 155-168. 
61. Peters, M.C., et al., COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med, 2020. 202(1): p. 83-90. 
62. Finney, L.J., et al., Inhaled corticosteroids downregulate the SARS- CoV-2 receptor ACE2 
in COPD through suppression of type I interferon. J Allergy Clin Immunol, 2021. 147(2): p. 510-519.e5. 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 69 63. Kern, C., et al., Modeling of SARS- CoV-2 Treatment Effects for Informed Drug 
Repurposing. Front Pharmacol, 2021. 12: p. 625678. 
64. Krolewiecki, A., et al., Antiviral effect of high -dose ivermectin in adults with COVID -19: 
A proof -of-concept randomized trial.  EClinicalMedicine, 2021. 37. 
65. Navarro, M., et al., Safety of high -dose ivermectin: a systematic review and meta -
analysis. J Antimicrob Chemother, 2020. 75(4): p. 827- 834. 
66. Smit, M.R., et al., Safety and mosquitocidal efficacy of high -dose ivermectin when co -
administered with dihydroartemisinin- pi[INVESTIGATOR_88509] ( IVERMAL): a randomised, double -blind, placebo- controlled trial. The Lancet 
Infectious Diseases, 2018. 18(6): p. 615- 626. 
67. Reis, G., et al., Effect of early treatment with fluvoxamine on risk of emergency care and 
hospi[INVESTIGATOR_740097] D-19: the TOGETHER randomised, platform 
clinical trial.  The Lancet Global Health, 2022. 10(1): p. e42- e51. 
68. Barré, J., J. -M. Sabatier, and C. Annweiler, Montelukast Drug May Improve COVID -19 
Prognosis: A Review of Evidence.  Frontiers in Pharmacology, 2020. 11(1344). 
69. Copertino, D.C., et al., Montelukast drug activity and potential against severe acute 
respi[INVESTIGATOR_6507] 2 (SARS -CoV-2). J Med Virol, 2021. 93 (1): p. 187 -
189. 
70. Sanghai, N. and G.K. Tranmer, Taming the cytokine storm: repurposing montelukast for 
the attenuation and prophylaxis of severe COVID -19 symptoms. Drug Discov Today, 
2020. 25(12): p. 2076- 2079. 
71. Al-Kuraishy, H.M., et al., Role of leukotriene pathway and montelukast in pulmonary and 
extrapulmonary manifestations of Covid -19: The enigmatic entity. Eur J Pharmacol, 
2021. 904: p. 174196. 
72. Mao, L., et al., Neurologic Manifestations of Hospi[INVESTIGATOR_358843] 2019 in Wuhan, China. JAMA Neurology, 2020. 77(6): p. 683- 690. 
73. Marschallinger, J., et al., Structural and functional rejuvenation of the aged brain by [CONTACT_436365] -asthmatic drug. Nat Commun, 2015. 6: p. 8466. 
74. Khan, A.R., et al., Montelukast in hospi[INVESTIGATOR_436329] -19. The 
Journal of asthma : official jo urnal of the Association for the Care of Asthma, 2021: p. 1-
7. 
75. Kerget, B., et al., Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID -19. J Med Virol, 2022. 94(5): p. 1950- 1958. 
   
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 70 16. Appendix A (Enrollment Closed 04FEB2022) – Ivermectin [ADDRESS_1011311] commonly reported adverse events for ivermectin are pruritus (25.3%), headache 
(13.9%), and dizziness (7.5%) (ICH working group, 2003). Since the 1980s, the use of 
ivermectin in humans for the treatment of filariasis, especially onchocerciasis, ha s been 
associated with SAEs, including coma, seizure and death only when administered in regions 
where onchocerciasis and loiasis  are co -endemic .[17]  
The issue of SAEs due to ivermectin is a threat to adherence to mass drug administration and the 
control and elimination of disease in communities co -endemic with  O. volvulus  and Loa . Mass 
drug administration  were suspended from 2004 to 2006 in some health zones in the Equateur, 
Bas Congo, and Oriental provinces in the D emocratic R epublic of the C ongo because of 
ivermectin -associated SAEs in the Bas Congo and Oriental provinces in 2003.[18]  It has been 
thought that c o-infection with L. loa is a risk factor for the development of these reactions. [19] 
Additionally, a study investigating escalating high doses of ivermectin in healt hy adults was 
performed to explore the safety of its use in the treatment of head lice. The authors documented 
no evidence of Central Nervous System ( CNS ) toxicity in doses up to [ADDRESS_1011312] FDA -
approved dose of 200 µg/kg.[20]  
Table 3 shows safety events that occurred in greater than 5% of the clinical trial population who received ≥  300 µ g/kg of ivermectin.[21]   For a detailed list of the adverse reactions th at occurred 
during clinical trials with ivermectin, refer to the product label and the Investigator’s Brochure . 
Ivermectin is pregnancy category C and is not contraindicated per FDA. Analyses of outcomes of pregnancies in women inadvertently exposed to i vermectin through mass administration 
campaigns show no evidence of increased birth defects, neonatal deaths, maternal morbidity, 
preterm births, or low birthweight over baseline rates. [22, 23]  
Table 3: Ivermectin Adverse Event Table for Doses ≥ 300 µ g/kg 
Indication (dose)  
Wuchererua bancrofti  
(200-400 µg/kg)  [24]  
Wuchererua bancrofti  
(200 µg/kg, then 400 
µg/kg on day 4)  [25]  
Stage II or III tungiasis 
lesions (300 µg/kg, 
days 1 & 2)  [26]  
Loa loa  infection (300 
or 400 µg/kg)  [27]  
Sympto matic 
Plasmodium 
falciparum  malaria 
(600 µg/kg)  [28] 
Adverse Reaction s 
Abdominal Pa in   7%   
Cough  42%     
Diarrhea     6.5%   
Eye disorders      9% 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 71 Fever  69% 46%  8%  
Gastrointestinal   18%    
Headache  75%  11% 16%  
Local Inflammation   9%    
Local Pain   9%    
Lumber myalgia     6.5%   
Malaise   27%    
Myalgia  37%     
Neurological   15%    
Pneumonia      9% 
Pruritus     60%  
Renal   33%    
Respi[INVESTIGATOR_696]   33%    
16.2. Additional Appendix -Level Exclusion Criteria  
1. End-stage renal disease on renal replacement therapy  
2. Liver failure  or decompensated cirrhosis  
3. Current or planned use of the following drugs during the study, listed by [CONTACT_156276]:  
a. Antiarrhythmic/antihypertensive drug class: quinidine, amiodarone, diltiazem, 
spi[INVESTIGATOR_8407], verapamil  
b. Antibiotic -macrolides drug class: clarithromycin, erythromycin  
c. Antifungal drug class: itraconazole, ketoconazole  
d. Immunosuppresant drug class: cyclosporine, t acrolimus  
e. Anti-HIV drug class: indinavir, ritonavir  
4. Nursing mothers  
5. Pregnancy*  
*Participants must agree to use an effective method of contraception during study drug 
administration and for at le ast 3 days after their final dose of study drug. Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
16.2.1. Precautions  
While rare, post -marketing reports indicate an increased International Normalized Ratio (INR) 
when ivermectin was co -administered with warfarin.  With a 3 -day dosing period this is unlikely 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011313]- spectrum, anti -parasitic agents isolated from Streptomyces avermitilis 
fermentation products. It binds selectively, and with high affinity, to glutamate -gated chloride 
ion channels, therefore increasing cell membrane permeability to chloride ions resulting in death 
of the parasite. [29] It is currently FDA -approved for the following indications: st rongyloidiasis 
of the intestinal tract due to the nemato de parasite Strongyloides stercoralis and onchocerciasis 
due to the nematode parasite Onchocerca volvulus.[21]  Per the FDA -approved labelling of 
ivermectin, the recommended dose is 200 µg/kg/day to treat strongyloidiases and 150 µg/kg/day 
to treat onchocerciasis in the form of a 3 mg tablet.    
16.3.1. Formulation, Appearance, Packaging, and Labeling  
Ivermectin is a white to yellowish -white, nonhygroscopic, crystalline powder. For this study, 
ivermectin will be supplied as fifteen 7- mg tablets in a bot tle with a single panel label . The 
tablets are white, round, biconvex tablets with “123” over the scoring on one side. All packaging 
will be labeled to indicate that the product is for investigational use.  
16.3.2. Drug Dispensing, Storage, and Stability  
Ivermectin will be supplied as [ADDRESS_1011314] be stored at temperatures below 30 °C. 
16.3.3. Dosing and Administration  
Ivermectin should be taken on an empty stomach with water  (30 minutes before a meal or 2 
hours after a meal). Each participant will receive a bottle of fifteen  7-mg tablets and will be 
instructed to take a pre -specified number of tablets for 3 consecutive days based on their weight 
(see Table 4 ) for a daily dose of approximately 300- 400 µg/kg . 
Table 4: Ivermectin 400  Dosing Schedule  
Weight (kg)  Day 1 (# of 7 -
mg tablets)  Day 2 (# of 7 -
mg tablets)  Day 3 (# of 7 -
mg tablets)  Daily Dose  
(µg/kg)  
35-52 2 2 2 269-400 
53-69 3 3 3 304-396 
70-89 4 4 4 315-400 
> 90 5 5 5 ≤ 389 
16.3.4. Rationale for Selection of Dose  
Pre-clinical studies:  
Reports from in vitro  studies suggest that ivermectin acts against ribonucleic acid ( RNA)  viruses 
such as SARS -CoV- [ADDRESS_1011315] importin α/β -mediated nuclear transport that prevent 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011316] cell function. [30] A single dose addition of 
ivermectin to Vero -hSLAM cells [ADDRESS_1011317] a 
5000- fold reduction in viral RNA at 48 hours  and may interfere with the attachme nt of SARS -
CoV- 2 spi[INVESTIGATOR_436331].[31, 32]  
Ivermectin has been shown to inhibit the replication of SARS -CoV- [ADDRESS_1011318] that ivermectin doses up to 100- fold 
higher than those approved for use in humans would be required to achieve the plasma 
concentrations necessary to duplicate the drug’s antiviral efficacy in vitro .[33, 34]  Even though 
ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, 
predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half -
maximal inhibitory concentration (IC 50) aga inst SARS -CoV- 2 in vitro .[35, 36]  
Ivermectin demonstra tes potential anti -inflammatory properties in some in vitro  
studies,  properties which have been postulated to be beneficial in the treatment of COVID -
19.[37 -39] The dose range for an anti -inflammatory effect may be lower than for the anti -viral 
effects. [39]   
Clinical studies:  
A number of retrospective cohort studies and the results of several randomized trials of 
ivermectin use in patients with COVID -[ADDRESS_1011319] been published in peer -reviewed journals or 
made available as preliminary, non -peer-reviewed reports. Some clinical studies showed no 
benefits after ivermectin use, whereas others reported shorter time to resolution of disease 
manifestations attributed to COVID -19, greater reduction in inflammatory markers, shorter time 
to viral clearance,  or lower mortality rates in patients who received ivermectin than in patients 
who received comparator drugs or placebo.[40 -45] 
Most of the studies reported to date are limited by [CONTACT_88568], varying dosing 
schedules and the adjunctive use of various concomitant medications (e.g., doxycycline, 
hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true 
efficacy or safety of ivermectin.  Clinical studies in outpatients with COVID -[ADDRESS_1011320] clinical trials of outpa tients with 
mild/moderate COVID -[ADDRESS_1011321] shown clinical improvement with even a single dose or a short 
two to five -day cours e of ivermectin given orally shortly after symptom onset. [34, 44, 46, 47]   
There is a dose- dependent relationship between i vermectin dos e and clinical efficacy. Trials 
using lower doses of ivermectin  tend to show no or minimal clinical benefit in COVID -19 
patients treated in the outpatient or hospi[INVESTIGATOR_6885]. [48, 49]  Higher doses, at least 0.4 mg/kg, 
particularly when administered in multiple doses , have been shown to significantly reduce time 
to recovery and mortality as compared with lower  doses or placebo/standard care.[46, 50- 52] 
There is a concentration -dependent virologic response seen using higher -than-usual doses of 
ivermectin (600 μg/kg vs 200 μg/kg once daily for 5 days)  that have been shown to significantly 
reduce the time to PCR viral positivity over standard doses with minimal associated 
toxicities. [47]  
The safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin was tested 
in healthy adult subjects .[33]  Doses from 30 mg/day (347- 571 µ g/kg)  to 120 mg/day (1404- 2000 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 74 µg/kg)  given for 3 days were all well tolerated .[33]  These data coupled with evidence of superior 
clinical efficacy of doses in the lower of this ran ge provide the rationale for the 300- 400 µ g/kg 
dose given f or 3 days in the proposed trial.  
16.4. Placebo Information  
16.4.1. Formulation, Appearance, Packaging, and Labeling  
Placebo will match the appearance of  the 7-mg ivermectin tablets: white, round, biconvex table ts 
with “123” over the scoring on one side . A total of fifteen  tablets will be  provided in a  bottle  
with a single panel label . The placebo formulation includes the following ingredients in a 210 mg 
tablet: microcrystalline cellulose, NF (MC -102; pregelatinized starch, NF  (Starch 1500) ; 
croscarmellose sodium, NF  (Vivasol, GF Grade) ; colloidal silicon d ioxide, NF  (Aerosil 200)  and 
magnesium stearate, NF (2257) . All packaging will be labeled to indicate that the product is for 
investigational use.  
16.4.2. Drug Dispensing, Storage, and Stability  
Placebo must be stored at temperatures below 30°C.  
16.4.3. Dosing and Administration  
Dosing and administration will occur according to Section 16.3.[ADDRESS_1011322]  
None  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 75 17. Appendix B  (Enrollment Closed 27May2022) – Fluvoxamine M aleate  
17.1. Risk Assessment  
The most common adverse effects of fluvoxamine described in the setting of  treatment of 
psychiatric conditions include gastrointestinal effects, neurological effects, dermatological 
reactions, and in rare cases suicidal ideation. [53] In two 10- week controlled trials in Obsessive 
Compulsive Disorder (OCD) and depression at doses ranging from 100- 300 mg/day, the most 
commonly observed adverse reactions associated with the use of fluvoxamine maleate tablets (incid ence of 5% or greater and at least twice that for placebo) were nausea, somnolence, 
insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, and vomiting (see Table 5) .[54]    
Table 6 lists the complete set of adverse events identified in a randomized clinical trial of 
fluvoxamine (300 mg/day for 15 days) versus placebo in 152 COVID -19 participants. [55] 
Adverse events and serious adver se events were more common in the placebo arm and the single 
SAE in the fluvoxamine  arm was dehydration and the study medication was not interrupted.[55]   
Table 5. Fluvoxamine Adverse events occurr ing in 10 -week studies of adult OCD or 
depression  
 *Table  shows events that  occurred in ≥ 5% of adult OCD and depression  study 
participants receiving 100 -300 mg/day for 10 weeks of fluvoxamine maleate versus 
placebo. [54] 
Adverse Reaction  Fluvoxamine, 
n=892 (%)  Placebo, 
n=778 (%)  
Headache  22 20 
Asthenia  14 6 
Nausea  40 14 
Diarrhea  11 7 
Constipation  10 8 
Dyspepsia  10 5 
Anorexia  6 2 
Vomiting  5 2 
Somnolence  22 8 
Insomnia  21 10 
Dry Mouth  14 10 
Nervousness  12 5 
Dizziness  11 6 
Tremor  5 1 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 76 Anxiety  5 3 
 
Table 6. Fluvoxamine Adverse events that occurred in COVID -19 study participants 
receiving 300 mg/day for 15 days. 
Adverse Reaction  [55] 
 Fluvoxamine, n=80 
(%) Placebo, n=72 
(%) 
Pneumonia  3.[ADDRESS_1011323] pain or tightness  0 2.8 
Fever  0 2.8 
Acute respi[INVESTIGATOR_1399]  0 1.4 
Serious adverse events  1.3 6.9 
Other adverse events  13.8 8.3 
17.2. Additional Appendix -Level Exclusion Criteria  
1. Use of selective serotonin  (or norepi[INVESTIGATOR_238])  reuptake inhibitors (SSRIs/SNRIs), 
including fluvoxamine, or monoamine oxidase inhibitors (MAOIs) within 2 
weeks of consent including triptans and tryptophan. Use of fluoxetine within 45 
days of consent.  
2. Co-administration of tizanidine, thioridazine, alosetron, pi[INVESTIGATOR_3924], diazepam, 
ramelteon , linezolid 
3. Bipolar Disorder  
4. Nursing mothers 
5. Pregnancy* 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 77 *Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tub al ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
17.2.1. Precaution s 
Fluvoxamine is a potent inhibitor of CYP1A2 and 2C19 and a moderate inhibitor of CYP2C9, 2D6, and 3A4, as such, it may enhance anticoagulant effects of antiplatelets and anticoagulants 
as well as other medications. It is recommended that concomitant medications listed below be 
discussed with participants and potential effects of increased drug exposure reviewed and 
monitored by [CONTACT_4538]/or their prescribing clinician.  
• Tricyclic antidepressants: monitor for side effects with amitriptyline, clomipramine, 
imipramine  
• Antipsychotic drugs: neuroleptic malignant syndrome or similar; particularly 
clozapi[INVESTIGATOR_050] (hypotension, seizure)  
• Benzodiazepi[INVESTIGATOR_1651]: particularly alprazolam; recommend dose reduction  
• Tramadol, buspi[INVESTIGATOR_5331], fentanyl, lithium, amphetamines, St. John’s Wart , 
carbamazepi[INVESTIGATOR_050], quinidine, and tacrine  
• Methadone: opi[INVESTIGATOR_9845]  
• Mexiletine: monitor for side effects  
• Theophylli ne: recommend dose reduction and monitor for side effects  
• Warfarin: monitor INR  
• NSAIDS or aspi[INVESTIGATOR_248]: monitor for signs of bleeding  
• Diltiazem, propranolol, metoprolol: monitor for bradycardia  
Participants should be warned about fluvoxamine inhibition of caffeine metabolism. A 
description is 1 cup of coffee has the effects of 4 cups while taking fluvoxamine .  
Caution should be used in participants with hepatic dysfunction due to approximately 30% 
increase in exposures .  
17.3. Fluvoxamine  Information  
Fluvoxamine  is an FDA -approved SSRI for the treatment of OCD. Clinically it is also used for 
other conditions such as depression.[53]  The active i ngredient in fluvoxamine is fluvoxamine 
maleate.  
17.3.1. Formulation, Appearance, Packaging, and Labeling  
Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has “APO” 
and the other side has “F50” with a partial bisect. All packagin g will be labeled to indicate that 
the product is for investigational use.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 78 17.3.2. Drug Dispensing, Storage, and Stability  
Drug will be supplied by [CONTACT_88570]. Study drug should be 
stored in controlled room temperature (20 °C to 25°C) ; excursions are permitted to 15 °C to 30°C . 
17.3.3. Dosing and Administration  
Fluvoxamine will be self -administered orally by [CONTACT_88571] a dose of 50 mg BID for 10 
days. 
17.3.4. Rationale for Selection of Dose  
The recommended starting dose of fluvoxamine for OCD in adults is 50 mg daily dose to be 
titrated up to a maximum of 300 mg/day divided into BID doses. Clinical data from the placebo -
controlled, randomized trial in nonhospi[INVESTIGATOR_88515] -19 demonstrated that a 
50 mg BID fluvoxamine dose was well -tolerated and effective (see Figure 5).[55] In the same 
study, doses of 100 mg BID in COVID -19 participants resulted in additional side effects over a 
14-day period. The 300 mg daily dose is for serotonin receptor activity, whereas the postulated 
dose for sigma -1 receptor activity as an anti -inflammatory is lower.  Therefore, the proposed 
dosing regimen of 50 mg BID for 10 days will use the anticipated minimal effective dos e to 
maximize efficacy and minimize toxicity.  
Pre-Clinical Studies : 
Pre-clinical studies have indicated that the anti -inflammatory effects of fluvoxamine may support 
its use for treating COVID -19. Systemic inflammation as a result of infection can damage 
vasculature which may lead to tissue hypoperfusion and multiple organ failure.[56]  Reducing 
systemic inflammation thereby  [CONTACT_740108]. In murine studies, administration of fluvoxamine significantly increased survival of 
S1R wildtype (WT) mice and S1R knockout (KO) mice challenged with ligand 
lipopolysaccharide (LPS) as compared to mice that received saline ( Figure 4). [56] Fluvoxamine 
also reduced production of inflammatory cytokines in ex vivo  and in vitro  murine and human 
cells (HEK293mTLR4/MD2/CD14, primary lung fibroblasts, and mouse bone marrow -derived 
macrophages) and inflammatory genes in human endothelial cells.[56, 57]  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 79  
Figure 4: Survival curve of WT and S1R KO mice  
Figure note: Mice were treated with vehicle (33% Kolliphor in saline) or STF (30 mg/kg) after 
administration of LPS (2 mg/kg) as indicated in (B) (n = 15 to 16 mice per group; **P < 0.01, ***P < 0.001, log- rank test). [56] 
Clinical Studies : 
A placebo -controlled, randomized trial in nonhospi[INVESTIGATOR_88515]- 19 tested the 
efficacy and safety of fluvoxamine (50 mg oral one-time dose, followed by 100 mg orally twice 
daily for 2 days, followed by 100 mg orally three times daily through day 15) versus placebo 
[55]. Results of the study reported that 8.3% (6/72) of participants who received placebo 
experienced clinical deterioration within 15 days of randomization, as opposed to 0% (0/80) in 
the fluvoxamine arm (absolute difference 8.7%; 95% CI, 1.8% to 16.5%;  P = 0.009) .[55]  
Clinical deterioration was  defined as shortness of breath /pneumonia with hypoxia  (Figure 5). 
Concomitant SSRI/SNRI dosing was not allowed per the trial protocol thus the  participant’s 
SSRI/SNRI was held for the study dosing period if reported at baseline .  

CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 80  
Figure 5:  Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early 
COVID- 19.  
A prospective, nonrandomized observational cohort study that evaluated fluvoxamine showed 
that on Day 14, 0/65 participants had persistent symptoms as opposed to 19/48 participants who 
did not receive fluvoxamine (P < 0.001)  [58] . Additionally, by [CONTACT_2006] 14, none of the participants 
who received fluvoxamine were hospi[INVESTIGATOR_88516] 6 participants who were 
hospi[INVESTIGATOR_88517] (see Figure 6). In this study, all participants were 
offered fluvoxamine and decided whether or not to take the study drug. Participants who chose to receive the study drug received 50 mg of fluvoxamine two time s a day following an upfront 100 
mg loading dose.[58]   
 
Figure 6:  Summary of study results for the prospective, nonrandomized observational 
cohort study with fluvoxamine in participants diagnosed with COVID -19.  

CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 81 17.4. Placebo Information  
The placebo will be a fluvoxamine -matched placebo containing mannitol, magnesium stearate, 
hydroxyethyl cellulose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and purified 
water . The appearance and packaging will match that of the study drug (as described in Section 
17.3.1). All packaging will be labeled to indicate that the product is for investigational use .  
17.4.1. Formulation, Appearance, Packaging, and Labeling  
Placebo will match the appearance of the fluvoxamine tablets: round golden 50 mg tablet that is 
scored on both sides - one side has “APO” and the other side has “F50” with a partial bisect. All 
packaging will be labeled to indicate that the produc t is for investigational use.  
17.4.2. Drug Dispensing, Storage, and Stability  
Placebo  will be supplied by [CONTACT_88570]. Placebo  should be 
stored in controlled room temperature (20°C to 25°C). 
17.4.3. Dosing and Administration  
Participants  will self -administer  one placebo tablet orally , twice daily for [ADDRESS_1011324]  
None  
 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 82 18. Appendix C (Enrollment Closed 08FEB2022)  – Fluticasone F uroate  
18.1. Risk Assessment  
The most common adverse reactions reported in ≥ 5% of adults and adolescents with lung 
disease include nasopharyngitis, bronchitis, upper respi[INVESTIGATOR_1092], and headache. 
Long- term use of systemic and local corticosteroid s may also result in the following side effects: 
Candida albicans  infection, immunosuppres sion, hypercorticism and adrenal suppression, 
reduction in bone mineral density (BMD), or glaucoma and cataracts.[59]  
There are insufficient data on the use of fluticasone furoat e in pregnant women. There are 
clinical considerations with use of fluticasone furoate  in pregnant women to inform drug-
associated risk  and benefit . In animal reproduction studies, fluticasone furoate administered by 
[CONTACT_654262]. The highest fluticasone furoate doses in the rat and rabbit studies were 4 times and 
1 times the maximum recommen ded human daily inhalation dose, respectively. The estimated 
risk of ma jor birth defects and miscarriage for the indicated populations is unknown. In the US 
general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.[59]  
Disease- Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately 
controlled asthma, there is an increased risk of several perinatal outcomes such as pre- eclampsia 
in the mother and prematurity, low birth weight, and small for gestational age in the neonate.[59]   
Table 7. Fluticasone Adverse reactions that occurred in  ≥3% of adults and adolescents 
with asthma in a 24 -week trial .  
Adverse Reaction  [59] Fluticasone furoate ,  
fluticasone 200 µg, n=119 
(%) Fluticasone furoate , 
fluticasone 100 µg, 
n=119 (%)  
Nasopharyngitis  [ADDRESS_1011325] infection  6 2 
Sinusitis  4 7 
Oropharyngeal pain  4 3 
Pharyngitis  3 6 
Back pain  3 3 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 83 Dysphonia  3 2 
Oral candidiasis  3 <1 
Procedural pain  3 <1 
Rhinitis  3 <1 
Throat irritation  3 <1 
Abdominal pain  3 0 
Cough 3 0 
18.2. Additional Appendix -Level Exclusion Criteria  
1. Severe hypersensitivity to milk proteins  
2. Currently prescribed or use within 30 days of inhaled or systemic steroids 
3. Moderate to severe hepatic impairment, defined as Child- Pugh B or C  
4. Nursing mothers  
5. Pregnancy*  
*Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
18.2.1. Precautions  
While not contraindicated, the following should be considered while taking fluticasone furoate : 
• Strong cytochrome P450 3A4 inhibitors ( e.g., ketoconazole, ritonavir, clarithromycin, 
conivaptan, indinavir, itraconazole, lopi[INVESTIGATOR_054], nefazodone, nelfinavir, sa quinavir, 
telithromycin, troleandomycin, voriconazole) should be used with caution as 
increased systemic corticosteroid adverse effects may occur in combination with 
fluticasone furoate. Generally, due to the limited study drug administration length, 
clinically significant interactions are unlikely.  
• Paradoxical Bronchospasm may occur with an immediate increase in wheezing after 
dosing. Fluticasone furoate should be discontinued immediately if this occurs.  
 
18.3. Fluticasone F uroate  Information  
Inhaled fluticasone furoate will be provided by [CONTACT_35316]. It is a synthetic trifluorinated 
inhaled corticosteroid ( ICS) with anti -inflammatory activity. In vitro  and in vivo  models have 
shown that fluticasone furoate demonstrates anti -inflammatory actions by [CONTACT_740109] -6 Protocol [v6.0] 
 
 84 glucocorticoid response element, inhibiting pre -inflammatory transcription factors such as 
NFkB, and inhibiting antigen- induced lung eosinophilia, which may contribute to its efficacy in 
the approved indications. It is FDA -approved for once -daily maintenance treatment of asthma as 
prophylactic therapy in patients 5 years and older. [59]  
18.3.1. Formulation, Appearance, Packaging, and Labeling  
Fluticasone furoate is an inhaled powder drug product. It  is a synthetic trifluorinated 
corticosteroid that is insoluble in water. Fluticasone furoate is a white powder. Fluticasone 
furoate  will be provided in a two tone gr ey inhaler with a  mouthpi[INVESTIGATOR_436333]. The blister strips used for this study will contain a white powder mix with a 
mixture of 2 00 µg micronized fluticasone furoate and l actose monohydrate. The inhaler will be 
packaged in a moisture -protective foil tray with a desiccant and a p eelable lid. [59] All packaging 
will be labeled to indicate that the product is for investigational use.  
18.3.2. Drug Dispensing, Storage, and Stability  
The study drug should be stored at  room temperature (20°C  to 25°C) with excursions permitted 
from 15°C to 30°C. It should be stored in a dry environment away from direct heat or sunlight. 
Unopened fluticasone furoate should be stored inside the unopened moisture -protective foil tray 
and only removed immediately before use. Any unused study product should be discarded 6 
weeks after opening the foil tray or when the counter reads “0” (after all blisters have been used), 
whichever comes first. The inhaler is not reusable .[59]  The study product has a shelf life of 24 
months when stored at ≤ 25°C . After removal of the secondary package and the desiccant packet 
from the inhaler, the product may be stored up to 6 weeks at  ≤ 25°C .  
18.3.3. Dosing and Administration  
Fluticasone furoate is a self -administered inhaled drug. Participants will self -administer 200 µg 
(1 blister) of fluticasone furoate once daily for 14 days. After inhaler activation, the powder 
within the blister is expo sed and the participant inhales the study drug through the mouthpi[INVESTIGATOR_13959].  
18.3.4. Rationale for Selection of Dose  
Inhaled corticosteroids (ICS) have been shown to be effective in improving asthma and as a combination therapy in chronic obstructive pulmonary disease (COPD) and thus are commonly 
prescribed medications world -wide. Corticosteroids have been shown to have a broad range of 
pharmacologic activity on multiple cell types including mast cells, eosinophils, neutrophils, macrophages and lymphocytes, as well as o ther mediators of inflammation such as histamine, 
eicosanoids, and leukotrienes. In addition to the anti -inflammatory role of ICS, there is also 
potential for regulation of gene transcription in epi[INVESTIGATOR_1663]. [60-62] This regulation of gene 
transcription may re sult in inhibition of SARS -CoV- 2 replication. Furthermore, in asthmatic 
patients , ICS may lower gene expression of ACE2 and TMPRSS2. T he ACE2 receptor is 
expressed on epi[INVESTIGATOR_436334] s SARS -CoV -2 for entry and the serine protease TMPRSS2 
primes the SARS -CoV- 2 spi[INVESTIGATOR_88520]. Lowering gene expression of ACE2 and 
TMPRSS2 may reduce binding and entry into cells therefore reducing or preventing infection.  
Clinical Studies:  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 85 The PRINCIPLE (Platform Randomized trial of Interventions against COVID -19 in Older 
People) trial is a multicenter, open -label, multi-arm, adaptive randomized, platform trial. The 
trial is ongoing and released an interim analysis after the Trial Steering Committee advised the 
Trial Management Group that the pre- specified superiority criterion was met on the time to 
recovery in the overall study population and the subgroup of participants with confirmed positive SARS -CoV- 2 testing. Participants were eligible if a ged >65 years, or > [ADDRESS_1011326] 14 days. Participants were randomized to any open active 
intervention arm including inhaled budesonide a nd usual care. Participants were followed 
through an online, daily symptom diary for 28 days. Participants received usual care plus inhaled 
budesonide 800 µg daily for 14 days or usual care alone. The primary outcome of the trial at the 
start was hospi[INVESTIGATOR_654251] 28 days; however, the rate of hospi[INVESTIGATOR_740098] a measure of illness duration. The t rial 
was completed with two co -primary endpoints measured within 28 days of randomization: 1) 
time to first reported recovery defined as the first day that a participant reported feeling recovered; and 2) hospi[INVESTIGATOR_88523]-19.  
The interim analysis included eligible SARS -CoV-2 positive participants who were randomized 
to inhaled budesonide (N=751) or usual care alone (N=1028). The mean age was 62.8 years and 83% of participants had co-morbidities. The median days from symptom onset t o enrollment was 
[ADDRESS_1011327]-recovery in the budesonide arm with an 
estimated median benefit of 3 days. The point estimate of the proportion of COVID-19 related hospi[INVESTIGATOR_88524] (8.5%) versus usual care (10.3%), 
but this did not meet statistical significance (95% BCI -0.7 – 4.8%). There were two SAE s for 
hospi[INVESTIGATOR_88525] -19, both in the budesonide group.  
A smaller trial of 146 nonhospi[INVESTIGATOR_119800] w ith mild COVID -19 reported that inhaled 
budesonide at the same dose reduced COVID- 19 related emergency assessments and 
hospi[INVESTIGATOR_059].  
The dose of ICS studied is PRINCIPLE is consistent with a high dose of inhaled steroid. The 
equivalent high dose of flu ticasone furoate is 200 µg/day. Inhaled fluticasone furoate has a 
greater anti -inflammatory potency per microgram than budesonide, thus fluticasone furoate is 
administered at a lower daily dose and used only once daily to achieve a similar high dose.  
18.4. Placebo Information  
18.4.1. Formulation, Appearance, Packaging, and Labeling  
The pla cebo will be a fluticasone furoate-matched placebo containing lactose for inhalation in 
the same two tone grey inhaler that is used for the study drug. The appearance and packaging 
will match that of the study drug (as described in Section 18.3.1). All packaging will be labeled 
to indicate that the product is for in vestigational use.  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 86 18.4.2. Drug Dispensing, Storage, and Stability  
Placebo will be stored in the same conditions as study drug, room temperature (20°C to 25°C) 
with excursions permitted from 15°C to 30°C in a dry environment away from direct heat or 
sunlight. The placebo has a shelf life of up to 36 months when stored at ≤ 30°C . 
18.4.3. Dosing and Administration  
Participants will self -administer one blister of placebo via inhalation from the inhaler once daily 
for [ADDRESS_1011328]  
None  
18.6. Safety Reporting for F luticasone Furoate  
Sponsor will promptly notify G laxoSmithKline of all SAEs, UADEs , and pregnancies (if 
applicable), and m edical device deficiencies that have occurred for participants enrolled in this 
Study Drug Appendix, in accordan ce with the timelines and procedures specified in the 
Protocol/appendix. In addition, the sponsor will reasonably obtain and provide follow -up 
information as available, to [COMPANY_004] upon request.  
 
  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 87 19. Appendix D – Ivermectin  600 
19.1. Risk Assessment  
Refer to Section 16.1.  
19.2. Additional Appendix -Level Exclusion Criteria  
Refer to Section 16.2.  
19.2.1. Precautions  
Refer to Section 16.2.1.  
19.3. Ivermectin  Information  
Refer to Section 16.3.  
19.3.1. Formulation, Appearance, Packaging, and Labeling  
Refer to Section 16.3.1.  
19.3.2. Drug Dispensing, Storage, and Stability  
Refer to Section 16.3.2.  
19.3.3. Dosing and Administration  
Ivermectin should be taken on an empty stomach with water (30 minutes before a meal or 2 
hours after a meal). Each participant will receive a bottle containing the number of 7 -mg tablets 
they require based on their weight and will be instructed to take a pre -specified number of tablets 
for 6 consecutive days based on their weight  (see Table 8) for a daily dose of approximately 
400-600 µg/kg. 
Table 8. Ivermectin 600  Dosing Schedule  
Weight 
(kg) Day 1 (# 
of 7-mg 
tablets)  Day 2 (# 
of 7-mg 
tablets)  Day 3 (# 
of 7-mg 
tablets)  Day 4 (# 
of 7-mg 
tablets)  Day 5  (# 
of 7-mg 
tablets)  Day 6  (# 
of 7-mg 
tablets)  Daily Dose 
(µg/kg)  
35-52 3 3 3 3 3 3 403-600 
53-69 4 4 4 4 4 4 406-528 
70-89 6 6 6 6 6 6 470-600 
90-109 7 7 7 7 7 7 450-540 
110-129 8 8 8 8 8 8 434-509 
> 129 10 10 10 10 10 10 < 540 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 88 19.3.4. Rationale for Selection of Dose 
Refer to Section 16.3.4.  
Additional relevant pre -clinical studies : 
Modeling studies have supported high dose and longer duration of ivermectin. One modeling 
study reported 600 µ g/kg daily for [ADDRESS_1011329]  while 300 µg/kg for [ADDRESS_1011330] efficacy. [63] Following th is modeling study, a  recent ly published proof -of-
concept randomized controlled clinical trial in hospi[INVESTIGATOR_436336] 600 µg/kg 
ivermectin for 5 days, a dose still well within the range for safety, wa s associated with IC 50 for 
anti-viral activity in vitro  while lower doses (300 µg/kg) were  not.[64]  The anti -viral act ivity was 
identified in the subgroup of patients on ivermectin with higher mean plasma concentrations. 
When the ivermectin group was further divided into subgroups with 160 ng/mL as the plasma 
concentration cutoff, the median Cmax achieved was 202 ng/mL in those with plasma 
concentration >160 ng/mL and this group had greater reduction in viral load at day 5. These data argue for the use of higher dosing regimens in clinical trials.  
The safety of higher doses of ivermectin is well understood. At least six published trials have 
administered ivermectin at doses above 400 µ g/kg.[65]  These include over 2,[ADDRESS_1011331] rations of cumulative 800 µ g/kg within one week and over 2,000 single dose 
administrations of 800 µ g/kg. The primary side effect of higher doses, usually due to peak 
concentrations, is transient and mild visual disturbances not found to be structural and f ound to 
self-resolve. One such study randomized 47 patients with malaria to receive ivermectin 600 
µg/kg daily for 3 days versus 300 µ g/kg daily for 3 days versus placebo.[66]  The 600 µ g/kg 
group had more adverse events than the other groups. Treatment -related adverse events exhibited 
a dose -response relationship, with predominantly transient minor  visual disturbances  that were 
deemed non -severe.  
19.4. Placebo Information  
Refer to Section 16.4.  
19.4.1. Formulation, Appearance, Packaging, and Labeling  
Refer to Section 16.4.1.  
19.4.2. Drug Dispensing, Storage, and Stability  
Refer to Section 16.4.2.  
19.4.3. Dosing and Administration  
Dosing and administration will occur according to Section 19.3.[ADDRESS_1011332]
 
• Photophobia  
• Blurre d vision 
• Visual impairment 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 89 20. Appendix E  – Fluvoxamine Maleate  100  
20.1. Risk Assessment  
Refer to Section 17.1.  
20.2. Additional Appendix -Level Exclusion Criteria  
Refer to Section 17.2.  
20.2.1. Precaution s 
Refer to Section 17.2.1.  
20.3. Fluvoxamine  Information  
Refer to  Section  17.3.  
20.3.1. Formulation, Ap pearance, Packaging, and Labeling  
Refer to Section 17.3.1. Fluvoxamine tablets remain 50 mg.  
20.3.2. Drug Dispensing, Storage, and Stability  
Refer to Section 17.3.2.  
20.3.3. Dosing and Administration  
Fluvoxamine will be self -administered orally by [CONTACT_88571] a dose of 50 mg BID for one 
day (first two dos es at 50 mg), followed by 100 mg (two 50 mg tablets) BID for 12 days 
(remaining 24 doses at 100 mg), for a total of 13 days (26 doses , 50 tablets ) of fluvoxamine.  
20.3.4. Rationale for Selection of Dose  
Refer to Section  17.3.4.  
Additional relevant rationale : 
The recommended starting dose of fluvoxamine for OCD in adults is 50 mg daily to be titrated 
up to a maximum of 300 mg/day divided into BID doses. Th e 300 mg daily dose is for serotonin 
receptor activity, whereas the postulated dose for sigma -1 receptor activity as an anti -
inflammatory is lower.  The TOGETHER trial is a randomized, placebo -controlled, adaptive 
platform trial that demonstrated a 100  mg B ID fluvoxamine dose  for 10 days  was well -tolerated 
and effective ( see Figure 7)  in nonhospi[INVESTIGATOR_88515] -19.[67]  This is a 
multicenter study conducted in Brazil. Participants were >  [ADDRESS_1011333] one risk factor for severe 
disease. Participants were randomized to active drug versus placebo, and due to  the concurrent 
enrollment into multiple active arms, pooled placebo was used for each active arm. The primary 
outcome was a composite endpoint of medical admission to the hospi[INVESTIGATOR_436337] -19, 
which was defined as more than 6 hours in an emergency car e setting (acute care areas set up to 
respond to capacity) or referral for hospi[INVESTIGATOR_059], within 28 days of randomization. Key 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 90 secondary outcomes included viral clearance, time to clinical improvement, and all -cause 
mortality. The planned accrual, based on an assumption of 15% event rate in the placebo group, 
was 681 participants per arm.  
The study randomized 741 participants to fluvoxamine and 756 to placebo. In the fluvoxamine 
group 79 (11%) participants had a primary out come event versus 119 (16%) in the pooled 
placebo arm (relative risk 0.68 [95% Bayesian credible interval, 0.52- .88]). Secondary outcomes 
including viral clearance at day 7, hospi[INVESTIGATOR_059], and mortality were not different between arms. There was no significant difference in the number  of treatment- emergent adverse events in the 
two arms. Thus, this large randomized, double -blind, controlled trial is suggestive of safety and 
efficacy of fluvoxamine dosed 100 mg twice daily in people with mild -to-moderate COVID- 19.  
 
Figure 7. Probability of efficacy for the primary outcome in the ITT and mITT populations 
of TOGETHER 
20.4. Placebo Information  
Refer to  Section  17.4.  
20.4.1. Formulation, Appearance, Packaging, and Labeling  
Refer to  Section  17.4.1.  
20.4.2. Drug Dispensing, Storage, and Stability  
Refer to  Section  17.4.2.  
20.4.3. Dosing and Administration  
Participants will self -administer one placebo tablet orally BID for one day, followed by [CONTACT_436370] (four total per day) for 12 days, for a tota l of 13 days of placebo 
tablets . 

CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011334]  
None  
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 92 21. Appendix F – Montelukast  
21.1. Risk Assessment  
The most common adverse reactions that occurred at a greater frequency in montelukast than in 
placebo and at an incidence rate ≥5% include upper respi[INVESTIGATOR_4416], fever, headache, 
pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, and 
otitis.  
Post-market reports of neuropsychiatric events associated with montelukast have included 
agitation, hostility, anxiousness, depression, sleepwalking, suicidal thinking/behavior, and 
tremors.  
Table 9. Montelukast sodium adverse reactions occurring at a higher incidence than 
placebo, in ≥1% of adults and adolescents ≥ [ADDRESS_1011335] sodium  
10 mg/day, n=1955 (%)  Placebo, n=1180 
(%) 
Pain, abdominal  2.9 2.5 
Asthenia/fatigue  1.[ADDRESS_1011336] Increase 1.6 1.2 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011337] that inhibits the cysteinyl leukotriene CysLT1 receptor. It is indicated for prophylaxis and chroni c treatment of asthma, acute prevention of exercise-
induced bronchoconstric tion, relief of seasonal allergic rhinitis, and  relief of perennial allergic 
rhinitis in patients ≥ [ADDRESS_1011338] tablets are beige, 
rounded square -shaped, biconvex, film -coated tablets, debossed “M10” on one side and plain on 
the other side . Each tablet contains 10.[ADDRESS_1011339] tablets should be stored at 25°C with excursi ons 
permitted from 15°C to 30°C, protected from moisture and light. 
21.3.3. Dosing and Administration  
Montelukast will be self -administered orally by [CONTACT_88571] a dose of 10 mg (1 tablet) 
once daily for 14 days.  
21.3.4. Rationale for Selection of Dose  
Preclinical Studies:  
Montelukast is a potent cysteinyl leukotriene receptor antagonist with anti- inflammatory effects 
and has been proven to significantly suppress oxidative stress and cytokine production. 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011340]’s ability to act as an anti -viral agent against 
RNA viruses such as Zika, Influenza A, and Hepatitis C , among others.[68]  A virtual screening 
tool, using an in silico molecular docking analysis, was used to simulate the binding of 
montelukast to catalytically active sites within the SARS‐CoV‐[ADDRESS_1011341] the main protease was −105.71, and the RNA dependent 
RNA polymerase was −104.75. These docking scores suggest that montelukast is likely to dock 
to both the main protease and the RNA dependent RNA polymerase of SARS‐CoV‐2, the refore 
demonst rating the potential to inhibit the enzymatic activity of the proteins and subsequently 
disrupting the substrate binding site.[69]    
Montelukast inhibits the signaling of NF -κB, such as interleukin- 6,8,10, TNF -alpha, MCP -1, and 
other proinflammatory mediators, which may result in a corresponding reduction of 
proinflammatory mediators, thereby [CONTACT_436372].[70] 
Pulmonary and extra -pulmonary manifestations in COVID -[ADDRESS_1011342].[71]  
In addition, 36.4% of patients with COVID -19 experience CNS involvement, and although the 
majority of these events include h eadache, anosmia, and dysgeusia;  more serious events such as 
stroke, delirium, and seizures have been reported.[72]  In a 6- week treatment of young (4 months) 
and old (20 months) rats with montelukast, a reduction of neuroinflammation was seen; elevation 
of hippocampal neurogenesis and improvement in learning and memory in old animals was seen. 
By [CONTACT_436373], the authors demonstrated that the effect 
was mediated through inhibition of the GPR17 receptor.[73]  
Clinical studies:  
One published retrospective analysis of hospi[INVESTIGATOR_226760] -[ADDRESS_1011343] (10 mg orally, once daily, at the discretion of the treating provider) 
included ninety- nine patients not previously on montelukast in the analysis ( [ADDRESS_1011344]/[ADDRESS_1011345]) . Inclusion required hospi[INVESTIGATOR_403403] [ADDRESS_1011346] was started 
on day 1 of hospi[INVESTIGATOR_436339] 1 were on hydroxychloroquine. Steroids were used by 16- 23% of patients during the first 3 days of hospi[INVESTIGATOR_5478] 33- 40% of patients 
during the entire hospi[INVESTIGATOR_059]. A univariate logistic regression revealed a lower risk of clinical 
deterioration in patients who were receiving montelukast, defined as any increase in ordinal scale 
from day 1 to day 3 of hospi[INVESTIGATOR_059], (OR, 0.23; P =.029); however, in a multivariable logistic 
regression, the results in patients [ADDRESS_1011347] was not significantly associated with a reduced risk of clinical deterioration (OR,  0.28; P =.058).[74]  
A recent prospective, randomized, controlled, single -blinded, single -center study investigated 
standard of care treatment versus two doses of montelukast (10 mg/day or 20 mg/day) in addition to standard of care treatment in hospi[INVESTIGATOR_226760] -19 at the Erzurum 
Regional Training and Research H ospi[INVESTIGATOR_436341].[75]  To be considered for enrollment, 
patients were required to h ave a PaO2/FiO2 ratio above [ADDRESS_1011348] of care treatment  (per Turkish Ministry of Health this was favipi[INVESTIGATOR_436342] a total of 5 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 95 days) . The primary outcome was  a composite of  progression to ARDS and/or  macrophage 
activati on syndrome (MAS) . MAS was assessed at Day 5 of treatment. Clinical outcomes of 
disease progression were captured during hospi[INVESTIGATOR_059]. Based on an assumption of a 20% or 
greater reduction in the primary outcome, the sample size was determined to be total accrual of 
180 participants enrolled (60 in each group). The two montelukast arms were combined for the 
clinical outcome analysis. The standard of care arm had more MAS or ARDS events (8 vs 3, p  = 
0.001)  and mortality (4 vs 0) than the pooled active trea tment arms. There was no adverse event 
reporting in this manuscript , and there are numerous weaknesses to the study design.  
Although the preclinical montelukast data available for SARS‐CoV‐[ADDRESS_1011349] propose a range of 
doses for testing (10 mg orally daily for 28- 60 days; 60 mg orally daily for 14 days), see Table 
10. One completed observational study ([STUDY_ID_REMOVED]5) has not posted study results. The proposed dose  (Section 21.3.3)  of [ADDRESS_1011350] 
Trial (COSMO) Phase 3, randomized, 
blinded, placebo-
controlled trial with 600 participants  10 mg daily for 60 
days [STUDY_ID_REMOVED] 
Efficacy of 
Montelukast in Mild -
moderate Respi[INVESTIGATOR_436343]- COVID-
19: (E -SPERANZA)  Phase 3, double -blind, 
randomized, placebo -
controlled trial with 284 participants  20 mg daily for 28 days [STUDY_ID_REMOVED] 
A National, Multi -
Center, Open- Label, 
Three -Arm, Phase II 
Study to Investigate 
the Effect of 
Montelukast Between Emergency Room 
Visits and 
Hospi[INVESTIGATOR_478647]- [ADDRESS_1011351] Treatment  Phase 2, 3 arm 
(montelukast , 
montelukast plus 
favicovir, and 
favicovir), open- label, 
randomized trial with 
[ADDRESS_1011352] arm 
dosing: 6x10 mg 
montelukast daily for 
14 days  [STUDY_ID_REMOVED] 
CONFIDENTIAL  ACTIV -6 Protocol [v6.0] 
 
 [ADDRESS_1011353] -matched placebo. The appearance and packaging will match 
that of the study drug (as described in Section 21.3.1).  
21.4.1. Formulation, Appea rance, Packaging, and Labeling  
Placebo will match the appearance of montelukast tablets: beige, rounded square -shaped, 
biconvex, film -coated tablets, debossed “M10” on one side and plain on the other side . All 
packaging will be labeled to indicate that the  product is for investigational use.  
21.4.2. Drug Dispensing, Storage, and Stability  
Placebo will be supplied by [CONTACT_740110]. 
Placebo should be stored at controlled room temperature 25°C, excursions permitted from 15°C 
to 30°C. 
21.4.3. Dosing and Administration  
Participants will self -administer one placebo tablet orally daily for [ADDRESS_1011354]  
Neuropsychiatric events including agitation, hostility, anxiousness, depression, sleepwalking, 
suicidal thinking/behavior, and tremors.  